<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antipsychotics for treatment of delirium in hospitalised non‐ICU patients - Burry, L - 2018 | Cochrane Library</title> <meta content="Antipsychotics for treatment of delirium in hospitalised non‐ICU patients - Burry, L - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005594.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antipsychotics for treatment of delirium in hospitalised non‐ICU patients - Burry, L - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005594.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD005594.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Antipsychotics for treatment of delirium in hospitalised non‐ICU patients" name="citation_title"/> <meta content="Lisa Burry" name="citation_author"/> <meta content="Mount Sinai Hospital, Leslie Dan Faculty of Pharmacy, University of Toronto" name="citation_author_institution"/> <meta content="lisa.burry@sinaihealthsystem.ca" name="citation_author_email"/> <meta content="Sangeeta Mehta" name="citation_author"/> <meta content="Mount Sinai Hospital, University of Toronto" name="citation_author_institution"/> <meta content="Marc M Perreault" name="citation_author"/> <meta content="Université de Montréal" name="citation_author_institution"/> <meta content="Jay S Luxenberg" name="citation_author"/> <meta content="On Lok" name="citation_author_institution"/> <meta content="Najma Siddiqi" name="citation_author"/> <meta content="Hull York Medical School, University of York" name="citation_author_institution"/> <meta content="Brian Hutton" name="citation_author"/> <meta content="Ottawa Hospital Research Institute" name="citation_author_institution"/> <meta content="Dean A Fergusson" name="citation_author"/> <meta content="Ottawa Hospital Research Institute" name="citation_author_institution"/> <meta content="Chaim Bell" name="citation_author"/> <meta content="Mount Sinai Hospital" name="citation_author_institution"/> <meta content="Louise Rose" name="citation_author"/> <meta content="Sunnybrook Health Sciences Centre and Sunnybrook Research Institute" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD005594.pub3" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/06/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005594.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005594.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005594.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antipsychotic Agents [adverse effects, *therapeutic use]; Benzodiazepines [adverse effects, therapeutic use]; Delirium [*drug therapy, mortality]; Haloperidol [adverse effects, therapeutic use]; Hospitalization; Olanzapine; Placebo Effect; Randomized Controlled Trials as Topic; Risperidone [adverse effects, therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005594.pub3&amp;doi=10.1002/14651858.CD005594.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005594.pub3&amp;doi=10.1002/14651858.CD005594.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005594.pub3&amp;doi=10.1002/14651858.CD005594.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005594.pub3&amp;doi=10.1002/14651858.CD005594.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005594.pub3&amp;doi=10.1002/14651858.CD005594.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005594.pub3&amp;doi=10.1002/14651858.CD005594.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005594.pub3&amp;doi=10.1002/14651858.CD005594.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005594.pub3&amp;doi=10.1002/14651858.CD005594.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005594.pub3&amp;doi=10.1002/14651858.CD005594.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005594.pub3&amp;doi=10.1002/14651858.CD005594.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005594.pub3&amp;doi=10.1002/14651858.CD005594.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005594.pub3&amp;doi=10.1002/14651858.CD005594.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005594.pub3&amp;doi=10.1002/14651858.CD005594.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005594.pub3&amp;doi=10.1002/14651858.CD005594.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005594.pub3&amp;doi=10.1002/14651858.CD005594.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005594.pub3&amp;doi=10.1002/14651858.CD005594.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005594.pub3&amp;doi=10.1002/14651858.CD005594.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005594.pub3&amp;doi=10.1002/14651858.CD005594.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005594.pub3&amp;doi=10.1002/14651858.CD005594.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005594.pub3&amp;doi=10.1002/14651858.CD005594.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005594.pub3&amp;doi=10.1002/14651858.CD005594.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005594.pub3&amp;doi=10.1002/14651858.CD005594.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005594.pub3&amp;doi=10.1002/14651858.CD005594.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="mvgXlmVk";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD005594\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD005594\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005594\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005594\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","ru","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD005594.pub3",title:"Antipsychotics for treatment of delirium in hospitalised non\\u2010ICU patients",firstPublishedDate:"Jun 18, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Dementia and Cognitive Improvement Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mvgXlmVk&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005594.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005594.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD005594.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD005594.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005594.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD005594.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD005594.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD005594.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD005594.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD005594.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>19612 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD005594.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/full#CD005594-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/full#CD005594-sec-0110"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/full#CD005594-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/full#CD005594-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/full#CD005594-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/full#CD005594-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/full#CD005594-sec-0067"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/full#CD005594-sec-0104"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/appendices#CD005594-sec-0115"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/table_n/CD005594StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/table_n/CD005594StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antipsychotics for treatment of delirium in hospitalised non‐ICU patients</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/information#CD005594-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Lisa Burry</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/information#CD005594-cr-0003">Sangeeta Mehta</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/information#CD005594-cr-0004">Marc M Perreault</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/information#CD005594-cr-0005">Jay S Luxenberg</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/information#CD005594-cr-0006">Najma Siddiqi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/information#CD005594-cr-0007">Brian Hutton</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/information#CD005594-cr-0008">Dean A Fergusson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/information#CD005594-cr-0009">Chaim Bell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005594.pub3/information#CD005594-cr-0010">Louise Rose</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/information/en#CD005594-sec-0128">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 June 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD005594.pub3">https://doi.org/10.1002/14651858.CD005594.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD005594-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005594-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD005594-abs-0002">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD005594-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005594-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005594-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD005594-abs-0001" lang="en"> <section id="CD005594-sec-0001"> <h3 class="title" id="CD005594-sec-0001">Background</h3> <p>Guidelines suggest limited and cautious use of antipsychotics for treatment of delirium where nonpharmacological interventions have failed and symptoms remain distressing or dangerous, or both. It is unclear how well these recommendations are supported by current evidence. </p> </section> <section id="CD005594-sec-0002"> <h3 class="title" id="CD005594-sec-0002">Objectives</h3> <p>Our primary objective was to assess the efficacy of antipsychotics versus nonantipsychotics or placebo on the duration of delirium in hospitalised adults. Our secondary objectives were to compare the efficacy of: 1) antipsychotics versus nonantipsychotics or placebo on delirium severity and resolution, mortality, hospital length of stay, discharge disposition, health‐related quality of life, and adverse effects; and 2) atypical vs. typical antipsychotics for reducing delirium duration, severity, and resolution, hospital mortality and length of stay, discharge disposition, health‐related quality of life, and adverse effects. </p> </section> <section id="CD005594-sec-0003"> <h3 class="title" id="CD005594-sec-0003">Search methods</h3> <p>We searched MEDLINE, Embase, Cochrane EBM Reviews, CINAHL, Thomson Reuters Web of Science and the Latin American and Caribbean Health Sciences Literature (LILACS) from their respective inception dates until July 2017. We also searched the Database of Abstracts of Reviews of Effects (DARE), Health Technology Assessment Database, Web of Science ISI Proceedings, and other grey literature. </p> </section> <section id="CD005594-sec-0004"> <h3 class="title" id="CD005594-sec-0004">Selection criteria</h3> <p>We included randomised and quasi‐randomised trials comparing 1) antipsychotics to nonantipsychotics or placebo and 2) typical to atypical antipsychotics for the treatment of delirium in adult hospitalised (but not critically ill) patients. </p> </section> <section id="CD005594-sec-0005"> <h3 class="title" id="CD005594-sec-0005">Data collection and analysis</h3> <p>We examined titles and abstracts of identified studies to determine eligibility. We extracted data independently in duplicate. Disagreements were settled by further discussion and consensus. We used risk ratios (RR) with 95% confidence intervals (CI) as a measure of treatment effect for dichotomous outcomes, and between‐group standardised mean differences (SMD) with 95% CI for continuous outcomes. </p> </section> <section id="CD005594-sec-0006"> <h3 class="title" id="CD005594-sec-0006">Main results</h3> <p>We included nine trials that recruited 727 participants. Four of the nine trials included a comparison of an antipsychotic to a nonantipsychotic drug or placebo and seven included a comparison of a typical to an atypical antipsychotic. The study populations included hospitalised medical, surgical, and palliative patients. </p> <p>No trial reported on duration of delirium. Antipsychotic treatment did not reduce delirium severity compared to nonantipsychotic drugs (standard mean difference (SMD) ‐1.08, 95% CI ‐2.55 to 0.39; four studies; 494 participants; very low‐quality evidence); nor was there a difference between typical and atypical antipsychotics (SMD ‐0.17, 95% CI ‐0.37 to 0.02; seven studies; 542 participants; low‐quality evidence). There was no evidence antipsychotics resolved delirium symptoms compared to nonantipsychotic drug regimens (RR 0.95, 95% CI 0.30 to 2.98; three studies; 247 participants; very low‐quality evidence); nor was there a difference between typical and atypical antipsychotics (RR 1.10, 95% CI 0.79 to 1.52; five studies; 349 participants; low‐quality evidence). The pooled results indicated that antipsychotics did not alter mortality compared to nonantipsychotic regimens (RR 1.29, 95% CI 0.73 to 2.27; three studies; 319 participants; low‐quality evidence) nor was there a difference between typical and atypical antipsychotics (RR 1.71, 95% CI 0.82 to 3.35; four studies; 342 participants; low‐quality evidence). </p> <p>No trial reported on hospital length of stay, hospital discharge disposition, or health‐related quality of life. Adverse event reporting was limited and measured with inconsistent methods; in those reporting events, the number of events were low. No trial reported on physical restraint use, long‐term cognitive outcomes, cerebrovascular events, or QTc prolongation (i.e. increased time in the heart's electrical cycle). Only one trial reported on arrhythmias and seizures, with no difference between typical or atypical antipsychotics. We found antipsychotics did not have a higher risk of extrapyramidal symptoms (EPS) compared to nonantipsychotic drugs (RR 1.70, 95% CI 0.04 to 65.57; three studies; 247 participants; very‐low quality evidence); pooled results showed no increased risk of EPS with typical antipsychotics compared to atypical antipsychotics (RR 12.16, 95% CI 0.55 to 269.52; two studies; 198 participants; very low‐quality evidence). </p> </section> <section id="CD005594-sec-0007"> <h3 class="title" id="CD005594-sec-0007">Authors' conclusions</h3> <p>There were no reported data to determine whether antipsychotics altered the duration of delirium, length of hospital stay, discharge disposition, or health‐related quality of life as studies did not report on these outcomes. From the poor quality data available, we found antipsychotics did not reduce delirium severity, resolve symptoms, or alter mortality. Adverse effects were poorly or rarely reported in the trials. Extrapyramidal symptoms were not more frequent with antipsychotics compared to nonantipsychotic drug regimens, and no different for typical compared to atypical antipsychotics. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD005594-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005594-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD005594-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD005594-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005594-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD005594-abs-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD005594-abs-0008">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005594-abs-0007">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD005594-abs-0005" lang="en"> <h3>Antipsychotics to treat delirium in hospitalised patients, not including those in intensive care units </h3> <p><b>Review question</b> </p> <p>We reviewed the evidence for the effectiveness and safety of antipsychotics for treatment of delirium in hospitalised patients, not including those in intensive care units (specialised wards for caring for very sick patients). </p> <p><b>Background</b> </p> <p>Delirium is a public health concern as it is a new onset confused state that increases the amount of time patients spend in the hospital, as well as their chance of dying. Guidelines recommendations include reversal of any potential medical or drug triggers that may be contributing to delirium. If delirium symptoms persist and are distressing or dangerous, an antipsychotic drug may be prescribed for a short time. Antipsychotic drugs, also known as tranquillizers, are mainly used to treat psychosis (e.g. hallucinations). There are two types of antipsychotics: first generation or typical antipsychotics (e.g. haloperidol) and second generation or atypical antipsychotics (e.g. quetiapine). Both groups of antipsychotics block the brain's dopamine receptor pathways but atypical antipsychotics also act on serotonin receptors. Atypical antipsychotics are also noted to be effective for treating both the positive symptoms (e.g. hallucinations) as well as the negative symptoms (e.g. emotional withdrawal) of psychosis. We need to understand if antipsychotics shorten the course of delirium or reduce symptoms or if they cause more harm. Therefore, we updated the existing Cochrane Review from 2007. </p> <p><b>Study characteristics</b> </p> <p>We found nine studies with 727 participants testing antipsychotics for delirium treatment; four trials compared an antipsychotic to another drug class or placebo and seven of the nine trials compared a typical antipsychotic to an atypical antipsychotic. </p> <p><b>Key findings</b> </p> <p>We found no evidence to support or refute the suggestion that antipsychotics shorten the course of delirium in hospitalised patients. Based on the available studies, antipsychotics do not reduce the severity of delirium or resolve symptoms compared to nonantipsychotic drugs or placebo or lower the risk of dying. We found no evidence to support or refute the suggestion that antipsychotics shorten hospital length of stay or improve health‐related quality of life. Side effects were rarely reported in the studies. </p> <p><b>Quality of the Evidence</b> </p> <p>It is important to note many clinically relevant outcomes were not reported in the studies and the overall quality of the available evidence was poor. </p> <p><b>External funding</b> </p> <p>Canadian Fraility Network (previously Technology Evaluation in the Elderly Network [TVN]) (www.cfn‐nce.ca/), Canada </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD005594-sec-0110" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005594-sec-0110">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005594-sec-0174">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD005594-sec-0110"></div> <h3 class="title" id="CD005594-sec-0111">Implications for practice</h3> <section id="CD005594-sec-0111"> <p> <ul id="CD005594-list-0003"> <li> <p>Survey data indicates pharmacological interventions, such as antipsychotics, are often used to manage delirium symptoms in clinical practice. The 2010 NICE guidelines (<a href="./references#CD005594-bbs2-0097" title="National Institute for Health and Clinical Excellence. Delirium: Diagnosis, Prevention, and Management (Clinical Guideline 103). www.nice.org.uk/CG103 (accessed 4 January 2015). ">NICE 2010</a>) recommended clinicians should investigate and manage underlying or reversible causes of delirium. For patients that are distressed, verbal and nonverbal techniques should be used to manage symptoms; if these strategies are ineffective or insufficient, short‐term (&lt; 1 week) antipsychotic drug might be considered at the lowest effective dose. </p> </li> <li> <p>After updating this review, we caution clinicians to the fact that there is still insufficient evidence overall on this subject. We found no evidence to determine whether antipsychotics reduce delirium duration in hospitalised non‐ICU patients (our primary objective). We found low‐quality evidence that antipsychotics do not reduce delirium severity compared to nonantipsychotic drugs or placebo and low‐quality evidence indicating there is no difference between typical and atypical antipsychotics. There is low‐quality evidence that antipsychotics do not alter mortality or adverse event rates in delirious hospitalised patients. </p> </li> </ul> </p> </section> <h3 class="title" id="CD005594-sec-0112">Implications for research</h3> <section id="CD005594-sec-0112"> <p> <ul id="CD005594-list-0004"> <li> <p>The 2010 NICE guidelines (<a href="./references#CD005594-bbs2-0097" title="National Institute for Health and Clinical Excellence. Delirium: Diagnosis, Prevention, and Management (Clinical Guideline 103). www.nice.org.uk/CG103 (accessed 4 January 2015). ">NICE 2010</a>) recommended that a large RCT should be conducted to compare typical antipsychotics and atypical antipsychotics with placebo in hospitalised patients with delirium. The NICE guidelines also recommended the study outcomes of such a trial should include recovery from delirium (defined as complete response), the duration and severity of delirium (measured with a validated tool), as well as clinically important adverse events. Such a trial has been completed for palliative care participants (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>) but not for other important hospitalised non‐ICU populations. </p> </li> </ul> <ul id="CD005594-list-0005"> <li> <p>Our search identified a number of delirium studies published in the last decade suggesting a growing interest in this subject. However, the majority of recent studies have focused on critically ill participants, still leaving us with insufficient poor quality data for hospitalised, non‐critically ill participants (e.g. general medicine, surgery). Given the limited available evidence for this review, the 2010 NICE guideline recommendations calling for new research is still justified in 2018. Well designed controlled trials are urgently needed to address this population who are frequently managed with antipsychotics despite limited evidence. In particular, we need adequately powered trials that include a placebo group and factor in nonpharmacological delirium treatment strategies that have already been shown to be helpful in this population to clarify if an antipsychotic alters delirium outcomes. These trials should clearly standardise and describe the use of rescue interventions to manage agitation (e.g. benzodiazepines and physical restraints), as such interventions are known to be associated with delirium and can introduce bias. </p> </li> </ul> <ul id="CD005594-list-0006"> <li> <p>Our search revealed limited data on outcomes that we deemed important for patients, their families, and the clinical team. Future studies need to examine the effect of therapy on duration of delirium or time to complete resolution, length of hospital stay, and long‐term outcomes, such as cognitive impairment. In addition, to improve comparison of results among trials there is a need for standardisation of research methods and outcomes reported, specifically duration of therapy and methods of evaluating response to delirium treatment. The Del‐COrS (Development of core outcome sets for effectiveness trial of interventions to prevent and/or treat delirium) group (<a href="./references#CD005594-bbs2-0109" title="RoseL , AgarM , BurryLD , CampbellN , ClarkeM , LeeJ , et al. Development of core outcome sets for effectiveness trials of interventions to prevent and/or treat delirium (Del‐COrS): study protocol. BMJ Open2017;7:e016371. [PUBMED: 28928181] ">Rose 2017</a>) is leading the development of international consensus on outcomes for trials of interventions to prevent and/or treat delirium for critically ill, acutely hospitalised participants, palliative care, and older adults. The recommendations from this group will be essential for future well designed delirium trials. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD005594-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD005594-sec-0036"></div> <div class="table" id="CD005594-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antipsychotics versus nonantipsychotics or placebo for the treatment of delirium in hospitalised patients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antipsychotics for the treatment of delirium in hospitalised patients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> delirious patients<br/> <b>Settings:</b> hospital wards, not ICU<br/> <b>Intervention:</b> antipsychotics drugs<br/> <b>Comparison: n</b>onantipsychotics drugs or placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Non‐antipsychotics drugs or Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Antipsychotics drugs</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration of delirium</b> </p> <p>Follow‐up: days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported in any trial.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Delirium severity</b><br/> DRS, DRS‐R98, MDAS<sup>1</sup><br/> Follow‐up: up to 10 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean DRS‐R‐98 score was was 22.7 (3.1) at baseline and 7.4 (SD 3.3) at the end of study.<sup>16</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised delirium severity score was <b>1.08 points lower</b> in the intervention group (2.55 lower to 0.39 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>494<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low‐quality</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.<sup>2,3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐1.08 (‐2.55 to 0.39)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Delirium resolution</b><br/> DRS, DRS‐R98<sup>1</sup><br/> Follow‐up: up to 10 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.95</b> <br/> (0.3 to 2.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>247<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low‐quality</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.<sup>6,7,8,9,10</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>268 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>254 per 1000</b><br/> (80 to 798) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>191 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>181 per 1000</b><br/> (57 to 569) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality</b><br/> Follow‐up: up to 10 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.29</b> <br/> (0.73 to 2.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>319<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low‐quality</b>: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<sup>11,12</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>163 per 1000</b><br/> (92 to 286) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>143 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>184 per 1000</b><br/> (104 to 325) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hospital length of stay</b> </p> <p>Follow‐up: days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported in any trial.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse Effects ‐ EPS</b> <br/> Extrapyramidal Symptom Rating Scale, or not reported<br/> Follow‐up: up to 10 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.7</b> <br/> (0.04 to 65.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>247<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low‐quality</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.<sup>13,14,15</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>91 per 1000</b><br/> (2 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>DRS</b> : Delirium Rating Scale; <b>DRS‐R98</b> = Delirium Rating Scale Revised 98; <b>EPS</b> : Extrapyramidal Symptoms; <b>MDAS</b> : Memorial Delirium Assessment Scale; <b>RR:</b> Risk ratio; <b>SD:</b> standard deviation </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> DRS = Delirium Rating Scale; DRS‐R98 = Delirium Rating Scale ‐Revised 98; MDAS = Memorial Delirium Assessment Scale<br/> <sup>2</sup> Only 1 of the 4 trials was considered low risk of bias across all domains. Three of the four trials had blinded delirium assessment.<br/> <sup>3</sup> Very high heterogeneity (97%).<br/> <sup>4</sup> Delirium severity was measured with different tools at variable time points.<br/> <sup>5</sup> Wide confidence interval that included both no effect and benefit.<br/> <sup>6</sup> All included trials had risk of bias.<br/> <sup>7</sup> Blinded delirium assessment for two of the three trials.<br/> <sup>8</sup> High degree of heterogeneity (83%)<br/> <sup>9</sup> Delirium resolution was measured with different tools at variable time points using different thresholds.<br/> <sup>10</sup> Wide confidence interval.<br/> <sup>11</sup> Only 1 trial had low risk of bias across all domains.<br/> <sup>12</sup> Low number of events.<br/> <sup>13</sup> All trials at risk of bias.<br/> <sup>14</sup> Variable tools used to assess.<br/> <sup>15</sup> Few events and wide confidence intervals. </p> <p><sup>16</sup> Assumed risk taken from <a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005594-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Typical versus atypical antipsychotics for treatment of delirium in hospitalised patients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Typical</b> versus<b>Atypical antipsychotics for treatment of delirium in hospitalised patients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> delirious patients<br/> <b>Settings:</b> hospital wards, not ICU<br/> <b>Intervention:</b> typical antipsychotic drug<br/> <b>Comparison:</b> atypical antipsychotic drug </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Atypical antipsychotic drug</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Typical antipsychotic drug</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration of delirium</b> </p> <p>Follow‐up: days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported in any trial.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Delirium resolution</b><br/> DRS, DRS‐R98<sup>1</sup><br/> Follow‐up: 7 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.1</b> <br/> (0.79 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>349<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low‐quality</b>: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>305 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>335 per 1000</b><br/> (241 to 463) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>313 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>344 per 1000</b><br/> (247 to 476) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Delirium severity</b><br/> DRS, DRS‐R98<sup>1</sup><br/> Follow‐up: 7 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean DRS‐R‐98 score was 29.7 (SD 4.6)</p> <p>8.0 (SD 6.9) at the end of study.<sup>10</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised delirium severity score was <b>0.17 points lower</b> in the intervention group (0.37 lower to 0.02 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>542<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low‐quality</b>: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.17 (‐0.37 to 0.02)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality</b><br/> Follow‐up: 7 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.71</b> <br/> (0.82 to 3.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>342<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low‐quality</b>: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>106 per 1000</b><br/> (51 to 219) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b><br/> (15 to 64) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hospital length of stay</b> </p> <p>Follow‐up: days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported in any trial.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse Effects ‐ EPS</b><br/> Follow‐up: 7 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 12.16</b> <br/> (0.55 to 269.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>198<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low‐quality</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.<sup>7,8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>DRS</b> : Delirium Rating Scale; <b>DRS‐R98</b> = Delirium Rating Scale Revised 98; <b>EPS</b> : Extrapyramidal Symptoms; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> DRS = Delirium Rating Scale; DRS‐R98 = Delirium Rating Scale Revised 98<br/> <sup>2</sup> All included trials had risk of bias.<br/> <sup>3</sup> Delirium resolution was measured with different tools at variable time points using different thresholds.<br/> <sup>4</sup> Only 1 of 7 trials was considered low risk of bias across all domains. Six of the seven trials had blinded delirium assessment.<br/> <sup>5</sup> Delirium severity was measured with different tools at variable time points.<br/> <sup>6</sup> Low number of events.<br/> <sup>7</sup> All trials at risk of bias.<br/> <sup>8</sup> Variable tools used to assess.<br/> <sup>9</sup> Few events and wide confidence intervals. </p> <p><sup>10</sup> Assumed risk taken from <a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD005594-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005594-sec-0037">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005594-sec-0138">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD005594-sec-0037"></div> <section id="CD005594-sec-0038"> <h3 class="title" id="CD005594-sec-0038">Description of the condition</h3> <p>Delirium is a dangerous and common syndrome among hospitalised patients (<a href="./references#CD005594-bbs2-0075" title="InouyeSK . Delirium in older persons. New England Journal of Medicine2006;354(11):1157‐65. ">Inouye 2006a</a>). It is estimated to be present in 8% to 17% of all older patients in the emergency department, and 29% to 64% of general medical and older adult inpatients (<a href="./references#CD005594-bbs2-0077" title="InouyeSK , WestendorpRG , SaczynskiJS . Delirium in elderly people. Lancet2014;383(9920):911‐22. ">Inouye 2014</a>). Delirium is most prevalent in frail individuals such as those with pre‐existing cognitive impairments (e.g. dementia), having undergone surgery, or suffering an acute infection or critical illness (<a href="./references#CD005594-bbs2-0077" title="InouyeSK , WestendorpRG , SaczynskiJS . Delirium in elderly people. Lancet2014;383(9920):911‐22. ">Inouye 2014</a>; <a href="./references#CD005594-bbs2-0111" title="RudolphJL , MarcantonioER . Review articles: postoperative delirium: acute change with long‐term implications. Anesthesia and Analgesia2011;112(5):1202‐11. ">Rudolph 2011</a>; <a href="./references#CD005594-bbs2-0113" title="SalluhJI , SoaresM , TelesJM , CerasoD , RaimondiN , NavaVS , et al. Delirium epidemiology in critical care (DECCA): an international study. Critical Care2010;14(6):R10. ">Salluh 2010</a>). </p> <p>The <i>Diagnostic and Statistical Manual of Mental Disorders</i> (DSM‐5) of the American Psychiatric Association defines delirium as a complex syndrome characterised by disturbances in attention (i.e. ability to focus, sustain or shift attention), awareness (i.e. orientation), and cognition (i.e. memory, perception) not explained by a pre‐existing neurocognitive disorder (<a href="./references#CD005594-bbs2-0052" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. Arlington: American Psychiatric Association, 2013. ">DSM‐V 2013</a>). Unlike dementia, the onset of delirium is rapid (i.e. over the course of hours or days); symptoms fluctuate and are typically reversible. The symptoms of delirium are unpredictable and irregular, contributing to its under‐detection (<a href="./references#CD005594-bbs2-0074" title="InouyeSK , ForemanMD , MionLC , KatzKH , CooneyLMJr . Nurses' recognition of delirium and its symptoms: comparison of nurse and researcher ratings. Archives of Internal Medicine2001;161(20):2467‐73. ">Inouye 2001</a>). Based on the predominance of type of psychomotor symptoms, delirium is categorized as hyperactive, hypoactive, or mixed (i.e. presenting with periods of both hyper‐ and hypoactivity) (<a href="./references#CD005594-bbs2-0047" title="ColeMG , CiampiA , BelzileE , ZhongL . Persistent delirium in older hospital patients: a systematic review of frequency and prognosis. Age &amp; Ageing2009;38(1):19‐26. ">Cole 2009</a>). </p> <p>The cause of delirium is thought to be multifactorial, dependent on a complex interplay of predisposing and precipitating factors (i.e. environment and iatrogenic(i.e. caused by medical examination or treatment) (<a href="./references#CD005594-bbs2-0060" title="GleasonOC . Delirium. American Family Physician2003;67(5):1027‐34. ">Gleason 2003</a>; <a href="./references#CD005594-bbs2-0108" title="RolfsonD . The causes of delirium. In: LindesayJRK , MacdonaldA editor(s). Delirium in Old Age. Oxford: Oxford University Press, 2002:101‐22. ">Rolfson 2002</a>), and mitigated or aggravated by a cascade of physiological events yet to be fully characterised. Predisposing risk factors are numerous and include advanced age, smoking and alcohol abuse, severe illness, and the presence of medical comorbidities such as hypertension and dementia (<a href="./references#CD005594-bbs2-0060" title="GleasonOC . Delirium. American Family Physician2003;67(5):1027‐34. ">Gleason 2003</a>; <a href="./references#CD005594-bbs2-0071" title="InouyeSK , CharpentierPA . Precipitating factors for delirium in hospitalized elderly persons. Predictive model and interrelationship with baseline vulnerability. Journal of the American Medical Association1996;275(11):852‐7. ">Inouye 1996</a>; <a href="./references#CD005594-bbs2-0077" title="InouyeSK , WestendorpRG , SaczynskiJS . Delirium in elderly people. Lancet2014;383(9920):911‐22. ">Inouye 2014</a>; <a href="./references#CD005594-bbs2-0108" title="RolfsonD . The causes of delirium. In: LindesayJRK , MacdonaldA editor(s). Delirium in Old Age. Oxford: Oxford University Press, 2002:101‐22. ">Rolfson 2002</a>; <a href="./references#CD005594-bbs2-0123" title="VasilevskisEE , HanJH , HughesCG , ElyEW . Epidemiology and risk factors for delirium across hospital settings. Best Practice &amp; Research Clinical Anaesthesiology2012;26:277–87. ">Vasilevskis 2012</a>). Patients with multiple risk factors appear to be sensitive to even minor precipitating insults, whereas those without such risk factors may develop delirium only following a major insult (e.g. sepsis). While the definitive cause of delirium is unknown, evidence suggests several biological networks may interact to cause the syndrome (<a href="./references#CD005594-bbs2-0125" title="WattDBD , KoziolLF . Delirium. In: NoggleC , DeanR editor(s). The Neuropsychology of Psychopathology. New York: Springer Publishing Company, 2013:425‐40. ">Watt 2013</a>). Postulated mechanisms include genetic factors, physiological stressors (e.g. inflammation, increased metabolism, decreased oxygenation, electrolyte imbalances), and disruptions in neurotransmitters involved in cognitive function (<a href="./references#CD005594-bbs2-0045" title="CerejeiraJ , FirminoHC , Vaz‐SerraA , Mukaetova‐LadinskaEB . The neuroinflammatory hypothesis of delirium. Acta Neuropathologica2010;119(6):737–54. ">Cerejeira 2010</a>; <a href="./references#CD005594-bbs2-0077" title="InouyeSK , WestendorpRG , SaczynskiJS . Delirium in elderly people. Lancet2014;383(9920):911‐22. ">Inouye 2014</a>). Several neurotransmitter systems have been implicated (<a href="./references#CD005594-bbs2-0057" title="GaudreauJD , GagnonP . Psychotogenic drugs and delirium pathogenesis: the central role of the thalamus. Medical Hypotheses2005;64(3):471‐5. ">Gaudreau 2005</a>), but a relative acetylcholine deficiency and/or dopamine excess are most supported by current literature (<a href="./references#CD005594-bbs2-0055" title="FlackerJM , LipsitzLA . Neural mechanisms of delirium: current hypotheses and evolving concepts. Journals of Gerontology. Series A: Biological Sciences and Medical Sciences1999;54(6):B239‐46. ">Flacker 1999</a>; <a href="./references#CD005594-bbs2-0067" title="HshiehTT , FongTG , MarcantonioER , InouyeSK . Cholinergic deficiency hypothesis in delirium: a synthesis of current evidence. Journals of Gerontology: Series A2008;63(7):764‐72. ">Hshieh 2008</a>; <a href="./references#CD005594-bbs2-0087" title="MaclullichAM , AnandA , DavisDH , JacksonT , BarughAJ , HallRJ , et al. New horizons in the pathogenesis, assessment and management of delirium. Age &amp; Ageing2013;42(6):667‐74. ">Maclullich 2013</a>; <a href="./references#CD005594-bbs2-0119" title="TrzepaczPT . Update on the neuropathogenesis of delirium. Dementia and Geriatric Cognitive Disorders1999;10(5):330‐4. ">Trzepacz 1999</a>; <a href="./references#CD005594-bbs2-0120" title="TrzepaczPT . Is there a final common neural pathway in delirium? Focus on acetylcholine and dopamine. Seminars in Clinical Neuropsychiatry2000;5(2):132‐48. ">Trzepacz 2000</a>; <a href="./references#CD005594-bbs2-0128" title="YoungBK , CamicioliR , GanziniL . Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment. Drugs &amp; Aging1997;10(5):367‐83. ">Young 1997</a>; ). </p> </section> <section id="CD005594-sec-0039"> <h3 class="title" id="CD005594-sec-0039">Description of the intervention</h3> <p>Current professional society guidelines direct the diagnosis, prevention, and management of delirium for patients in various hospital settings (<a href="./references#CD005594-bbs2-0031" title="BarrJ , FraserGL , PuntilloK , ElyEW , GelinasC , DastaJF , et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Critical Care Medicine2013;41(1):263‐306. ">Barr 2013</a>; <a href="./references#CD005594-bbs2-0038" title="British Geriatric Society. Clinical guidelines for the prevention, diagnosis and management of delirium in older people in hospital. www.bgs.org.uk/Publications/Clinical%20Guidelines/clinical_1‐2_fulldelirium.htm (accessed 1 December 2014). ">British Geriatric Society 2006</a>; <a href="./references#CD005594-bbs2-0097" title="National Institute for Health and Clinical Excellence. Delirium: Diagnosis, Prevention, and Management (Clinical Guideline 103). www.nice.org.uk/CG103 (accessed 4 January 2015). ">NICE 2010</a>; <a href="./references#CD005594-bbs2-0105" title="Royal College of Psychiatrists. The prevention, diagnosis and management of delirium in older people (National Guidelines). www.rcplondon.ac.uk/sites/default/files/concise‐delirium‐2006.pdf (accessed 11 December 2014). ">RCP 2006</a>). The recommended first steps in delirium care involve identifying and reversing potential precipitating medical conditions, mitigating environmental triggers, and minimising drug exposures. Different combinations of strategies have been used and include resolving acute medical issues, managing pain, applying reorientation strategies, normalising the sleep‐wake cycle, ensuring safe mobilisation, and evaluating potential drug‐related causes (<a href="./references#CD005594-bbs2-0056" title="FosnightS . Delirium in the elderly. In: RichardsonM , ChantC , ChessmanKH , FinksSW , HemstreetBA , HumeAL , et.al editor(s). Pharmacotherapy Self‐Assessment Program. 7th Edition. Lenexa: American College of Clinical Pharmacy, 2011:73‐95. ">Fosnight 2011</a>; <a href="./references#CD005594-bbs2-0076" title="InouyeSK , BakerDI , FugalP , BradleyEH , Project HD. Dissemination of the hospital elder life program: implementation, adaptation, and successes. Journal of the American Geriatrics Society2006;54(10):1492‐9. ">Inouye 2006b</a>; <a href="./references#CD005594-bbs2-0077" title="InouyeSK , WestendorpRG , SaczynskiJS . Delirium in elderly people. Lancet2014;383(9920):911‐22. ">Inouye 2014</a>; <a href="./references#CD005594-bbs2-0086" title="LundstromM , EdlundA , KarlssonS , BrannstromB , BuchtG , GustafsonY . A multifactorial intervention program reduces the duration of delirium, length of hospitalization, and mortality in delirious patients. Journal of the American Geriatrics Society2005;53(4):622‐8. ">Lundstrom 2005</a>). Numerous classes of psychoactive drugs (e.g. antipsychotics, benzodiazepines, opioids, alpha‐2 agonists, and cholinesterase inhibitors) have been studied for their effect on delirium in various patient populations. However, data are inconsistent and practice remains largely governed by clinical circumstance and physician discretion. Because of the uncertainty surrounding antipsychotic effectiveness in delirium, professional societies recommend limited and cautious use, and only in cases where nonpharmacological approaches have failed and symptoms remain distressing or dangerous, or both, to the patient or healthcare staff, or both (<a href="./references#CD005594-bbs2-0030" title="American Psychiatric Association. Practice guidelines for the treatment of patients with delirium. American Journal of Psychiatry1999;156 Suppl:1‐20. ">American Psychiatric Association 1999</a>; <a href="./references#CD005594-bbs2-0044" title="Clinical Epidemiology and Health Service Evaluation Unit, Melbourne Health and the Australian Health Ministers’ Health Care of Older Australians Standing Committee. Clinical Practice Guidelines for the Management of Delirium in Older People. www.health.vic.gov.au/acute‐agedcare/ (accessed 1 February 2015). ">CEHSE 2006</a>; <a href="./references#CD005594-bbs2-0097" title="National Institute for Health and Clinical Excellence. Delirium: Diagnosis, Prevention, and Management (Clinical Guideline 103). www.nice.org.uk/CG103 (accessed 4 January 2015). ">NICE 2010</a>). </p> <p>Antipsychotic drug exposure is associated with notable risk that should be considering when prescribing. Studies conducted in older adult patients have shown an approximate two‐fold increase in risk of cardiac or cerebrovascular incidents ‐ similar in magnitude irrespective of antipsychotic class (i.e. typical and atypical antipsychotics) ‐ even with short term use (<a href="./references#CD005594-bbs2-0058" title="GillSS , BronskillSE , NormandSL , AndersonGM , SykoraK , LamK , et al. Antipsychotic drug use and mortality in older adults with dementia. Annals of Internal Medicine2007;146(11):775‐86. ">Gill 2007</a>; <a href="./references#CD005594-bbs2-0093" title="MittalV , KurupL , WilliamsonD , MuraleeS , TampiRR . Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. American Journal of Alzheimer's Disease and Other Dementias2011;26(1):10‐28. ">Mittal 2011</a>; <a href="./references#CD005594-bbs2-0104" title="RayWA , ChungCP , MurrayKT , HallK , SteinCM . Atypical antipsychotic drugs and the risk of sudden cardiac death. New England Journal of Medicine2009;360(3):225‐35. ">Ray 2009</a>; <a href="./references#CD005594-bbs2-0124" title="WangPS , SchneeweissS , AvornJ , FischerMA , MogunH , SolomonDH , et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. New England Journal of Medicine2005;353(22):2335‐41. ">Wang 2005</a>). Increased mortality risk was found in one meta‐analysis (<a href="./references#CD005594-bbs2-0115" title="SchneiderLS , DagermanKS , InselP . Risk of death with atypical antipsychotic drug treatment for dementia: meta‐analysis of randomized placebo‐controlled trials. Journal of the American Medical Association2005;294(15):1934‐43. ">Schneider 2005</a>) of 17 placebo‐controlled trials of atypical antipsychotics (or second generation antipsychotics) in dementia patients. As a consequence, the US Food and Drug Administration (FDA) issued their strictest warning label or a 'black box' warning for all antipsychotic drugs due to the association with serious hazard when used in the older adult patients. A black box warning is applied to drug labelling by the FDA when there is reasonable evidence of an association of serious and, sometimes, life‐threatening adverse events. Antipsychotics have also been shown to paradoxically worsen delirium severity in some patients (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>). These are important findings, as delirious patients are often frail and have multiple comorbidities (<a href="./references#CD005594-bbs2-0077" title="InouyeSK , WestendorpRG , SaczynskiJS . Delirium in elderly people. Lancet2014;383(9920):911‐22. ">Inouye 2014</a>). Despite the known risks and lack of strong data showing consistent benefit, physician surveys (<a href="./references#CD005594-bbs2-0043" title="CarnesM , HowellT , RosenbergM , FrancisJ , HildebrandC , KnuppelJ . Physicians vary in approaches to the clinical management of delirium. Journal of the American Geriatrics Society2003;51(2):234‐9. ">Carnes 2003</a>; <a href="./references#CD005594-bbs2-0091" title="MeagherDJ . Impact of an educational workshop upon attitudes towards pharmacotherapy for delirium. International Psychogeriatrics2010;22(6):938‐46. ">Meagher 2010</a>) and observational data (<a href="./references#CD005594-bbs2-0037" title="BriskmanI , DubinskiR , BarakY . Treating delirium in a general hospital: a descriptive study of prescribing patterns and outcomes. International Psychogeriatrics2010;22(2):328‐31. ">Briskman 2010</a>; <a href="./references#CD005594-bbs2-0064" title="HattaK , KishiY , WadaK , OdawaraT , TakeuchiT , ShiganamiT , et al. Antipsychotics for delirium in the general hospital setting in consecutive 2453 inpatients: a prospective observational study. International Journal of Geriatric Psychiatry2014;29(3):253‐62. ">Hatta 2014</a>) show exceedingly high use of antipsychotics in hospitalised delirious patients (77% to 87%). </p> </section> <section id="CD005594-sec-0040"> <h3 class="title" id="CD005594-sec-0040">How the intervention might work</h3> <p>While relative excess of the neurotransmitter dopamine remains a leading hypothesised neurochemical substrate for delirium (<a href="./references#CD005594-bbs2-0067" title="HshiehTT , FongTG , MarcantonioER , InouyeSK . Cholinergic deficiency hypothesis in delirium: a synthesis of current evidence. Journals of Gerontology: Series A2008;63(7):764‐72. ">Hshieh 2008</a>; <a href="./references#CD005594-bbs2-0119" title="TrzepaczPT . Update on the neuropathogenesis of delirium. Dementia and Geriatric Cognitive Disorders1999;10(5):330‐4. ">Trzepacz 1999</a>; <a href="./references#CD005594-bbs2-0120" title="TrzepaczPT . Is there a final common neural pathway in delirium? Focus on acetylcholine and dopamine. Seminars in Clinical Neuropsychiatry2000;5(2):132‐48. ">Trzepacz 2000</a>; <a href="./references#CD005594-bbs2-0128" title="YoungBK , CamicioliR , GanziniL . Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment. Drugs &amp; Aging1997;10(5):367‐83. ">Young 1997</a>), few studies have examined neurotransmitter metabolism in the context of delirium trajectory (<a href="./references#CD005594-bbs2-0116" title="ThomasC , HestermannU , KopitzJ , PlaschkeK , OsterP , DriessenM , et al. Serum anticholinergic activity and cerebral cholinergic dysfunction: an EEG study in frail elderly with and without delirium. BMC Neuroscience2008;9:86. ">Thomas 2008</a>; <a href="./references#CD005594-bbs2-0122" title="Van derCammenTJ , TiemeierH , EngelhartMJ , FekkesD . Abnormal neurotransmitter metabolite levels in Alzheimer patients with a delirium. International Journal of Geriatric Psychiatry2006;21(9):838‐43. ">Van der Cammen 2006</a>). The therapeutic effects of antipsychotics in delirium remain unknown, but it is postulated their effects may be mediated through a reduction of psychotic symptoms (also known as positive symptoms for patients with schizophrenia), or through sedation. There are two types of antipsychotics: first generation, also known as typical antipsychotics, (e.g. haloperidol, chlorpromazine) and second generation, also known as atypical antipsychotics, (e.g. quetiapine, olanzapine, risperidone). Both groups of antipsychotics block the brain's dopamine receptor pathways but atypical antipsychotics also act on serotonin receptors. Both are effective for managing the positive symptoms in schizophrenia (e.g. psychosis, hallucinations, agitation) but atypical antipsychotics also improve the negative symptoms such as emotional and social withdrawal. </p> <p>Antipsychotics are thought to help with the psychotic symptoms of delirium but have also been shown useful in individuals who have hypoactive symptoms (<a href="./references#CD005594-bbs2-0032" title="BoettgerSB , BreitbartW , PassikS . Haloperidol and risperidone in the treatment of delirium and its subtypes. European Journal of Psychiatry2011;25(2):59‐67. ">Boettger 2011a</a>; <a href="./references#CD005594-bbs2-0033" title="BoettgerS , FriedlanderM , BreitbartW , PassikS . Aripiprazole and haloperidol in the treatment of delirium. Australian and New Zealand Journal of Psychiatry2011;45(6):477‐82. ">Boettger 2011b</a>; <a href="./references#CD005594-bbs2-0036" title="BreitbartW , TremblayA , GibsonC . An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics2002;43(3):175‐82. ">Breitbart 2002b</a>; <a href="./references#CD005594-bbs2-0078" title="ItoT , OkuboY . Aripiprazole in the treatment of hypoactive subtype of delirium with terminal cancer patients. Proceedings of the Academy of Psychosomatic Medicine. 2007:31. ">Ito 2007</a>; <a href="./references#CD005594-bbs2-0102" title="PlattMM , BreitbartW , SmithM , MarottaR , WeismanH , JacobsenPB . Efficacy of neuroleptics for hypoactive delirium. Journal of Neuropsychiatry and Clinical Neuroscience1994;6(1):66‐7. ">Platt 1994</a>). Studies investigating changes in individual delirium symptomatology in the context of antipsychotic treatment have yielded conflicting results. It appears both cognitive and noncognitive symptoms may improve to varying extents. Specifically, where some studies demonstrate a similar trajectory for both types of symptoms (<a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a>; <a href="./references#CD005594-bbs2-0080" title="KimKY , BaderGM , KotlyarV , GropperD . Treatment of delirium in older adults with quetiapine. Journal of Geriatric Psychiatry and Neurology2003;16(1):29‐31. ">Kim 2003</a>; <a href="./references#CD005594-bbs2-0082" title="LeonardM , AdamisD , SaundersJ , TrzepaczP , MeagherD . A longitudinal study of delirium phenomenology indicates widespread neural dysfunction. Palliative and Supportive Care2015;13(2):187‐96. ">Leonard 2015</a>; <a href="./references#CD005594-bbs2-0092" title="MeagherD , AdamisD , TrzepaczP , LeonardM . Features of subsyndromal and persistent delirium. British Journal of Psychiatry2012;200(1):37‐44. ">Meagher 2012</a>; <a href="./references#CD005594-bbs2-0099" title="ParelladaE , BaezaI , DePabloJ , MartinezG . Risperidone in the treatment of patients with delirium. Journal of Clinical Psychiatry2004;65(3):348‐53. ">Parellada 2004</a>; <a href="./references#CD005594-bbs2-0114" title="SasakiY , MatsuyamaT , InoueS , SunamiT , InoueT , DendaK , et al. A prospective, open‐label, flexible‐dose study of quetiapine in the treatment of delirium. Journal of Clinical Psychiatry2003;64(11):1316‐21. ">Sasaki 2003</a>), others show a more rapid recovery of noncognitive disturbances (e.g. inattention and disorientation) (<a href="./references#CD005594-bbs2-0049" title="DevlinJW , SkrobikY , RikerRR , HinderleiderE , RobertsRJ , FongJJ , et al. Impact of quetiapine on resolution of individual delirium symptoms in critically ill patients with delirium: a post‐hoc analysis of a double‐blind, randomized, placebo‐controlled study. Critical Care2011;15(5):R215. ">Devlin 2011</a>; <a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>). </p> </section> <section id="CD005594-sec-0041"> <h3 class="title" id="CD005594-sec-0041">Why it is important to do this review</h3> <p>Studies have shown an association between delirium and adverse outcomes such as prolonged length of hospital stay, increased hospital mortality, and higher rates of hospital readmission, institutionalisation, and functional and cognitive decline, even after adjustment for comorbidities and illness severity (<a href="./references#CD005594-bbs2-0042" title="BuurmanBM , HoogerduijnJG , DeHaanRJ , Abu‐HannaA , LagaayAM , VerhaarHJ , et al. Geriatric conditions in acutely hospitalized older patients: prevalence and one‐year survival and functional decline. PLOS One2011;6(11):e26951. ">Buurman 2011</a>; <a href="./references#CD005594-bbs2-0063" title="HanJH , ShintaniA , EdenS , MorandiA , SolbergLM , SchnelleJ , et al. Delirium in the emergency department: an independent predictor of death within 6 months. Annals of Emergency Medicine2010;56(3):244‐52. ">Han 2010</a>; <a href="./references#CD005594-bbs2-0072" title="InouyeSK , RushingJT , ForemanMD , PalmerRM , PompeiP . Does delirium contribute to poor hospital outcomes? A three‐site epidemiologic study. Journal of General Internal Medicine1998;13(4):234‐42. ">Inouye 1998</a>; <a href="./references#CD005594-bbs2-0079" title="KakumaR , Du FortGG , ArsenaultL , PerraultA , PlattRW , MonetteJ , et al. Delirium in older emergency department patients discharged home: effect on survival. Journal of the American Geriatric Society2003;51(4):443‐50. ">Kakuma 2003</a>; <a href="./references#CD005594-bbs2-0083" title="LeslieDL , ZhangY , HolfordTR , BogardusST , Leo‐SummersLS , InouyeSK . Premature death associated with delirium at 1‐year follow‐up. Archives of Internal Medicine2005;165(14):1657‐62. ">Leslie 2005</a>; <a href="./references#CD005594-bbs2-0085" title="LevkoffSE , EvansDA , LiptzinB , ClearyPD , LipsitzLA , WetleTT , et al. Delirium. The occurrence and persistence of symptoms among elderly hospitalized patients. Archives of Internal Medicine1992;152(2):334‐40. ">Levkoff 1992</a>; <a href="./references#CD005594-bbs2-0088" title="McCuskerJ , ColeM , DendukuriN , BelzileE , PrimeauF . Delirium in older medical inpatients and subsequent cognitive and functional status: a prospective study. Canadian Medical Association Journal2001;165(5):575‐83. ">McCusker 2001</a>; <a href="./references#CD005594-bbs2-0089" title="McCuskerJ , ColeM , AbrahamowiczM , PrimeauF , BelzileE . Delirium predicts 12‐month mortality. Archives of Internal Medicine2002;162(4):457‐63. ">McCusker 2002</a>; <a href="./references#CD005594-bbs2-0101" title="PitkalaKH , LaurilaJV , StrandbergTE , TilvisRS . Prognostic significance of delirium in frail older people. Dementia and Geriatric Cognitive Disorders2005;19(2‐3):158‐63. ">Pitkala 2005</a>; <a href="./references#CD005594-bbs2-0103" title="PompeiP , ForemanM , RudbergMA , InouyeSK , BraundV , CasselCK . Delirium in hospitalized older persons: outcomes and predictors. Journal of the American Geriatrics Society1994;42(8):809‐15. ">Pompei 1994</a>; <a href="./references#CD005594-bbs2-0107" title="RizzoJA , BogardusSTJr , Leo‐SummersL , WilliamsCS , AcamporaD , InouyeSK . Multicomponent targeted intervention to prevent delirium in hospitalized older patients: what is the economic value?. Medical Care2001;39(7):740‐52. ">Rizzo 2001</a>; <a href="./references#CD005594-bbs2-0127" title="WitloxJ , EurelingsLS , DeJongheJF , KalisvaartKJ , EikelenboomP , VanGoolWA . Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta‐analysis. Journal of the American Medical Association2010;304(4):443‐51. ">Witlox 2010</a>). Delirium is also known to cause distress to patients, their families, and clinical staff (<a href="./references#CD005594-bbs2-0035" title="BreitbartW , GibsonC , TremblayA . The delirium experience: delirium recall and delirium‐related distress in hospitalized patients with cancer, their spouses/caregivers, and their nurses. Psychosomatics2002;43(3):183‐94. ">Breitbart 2002a</a>; <a href="./references#CD005594-bbs2-0039" title="BrueraE , BushSH , WilleyJ , ParaskevopoulosT , LiZ , PalmerJL , et al. Impact of delirium and recall on the level of distress in patients with advanced cancer and their family caregivers. Cancer2009;115(9):2004‐12. ">Bruera 2009</a>; <a href="./references#CD005594-bbs2-0041" title="BussMK , VanderwerkerLC , InouyeSK , ZhangB , BlockSD , PrigersonHG . Associations between caregiver‐perceived delirium in patients with cancer and generalized anxiety in their caregivers. Journal of Palliative Medicine2007;10(5):1083‐93. ">Buss 2007</a>; <a href="./references#CD005594-bbs2-0046" title="CohenMZ , PaceEA , KaurG , BrueraE . Delirium in advanced cancer leading to distress in patients and family caregivers. Journal of Palliative Care2009;25(3):164‐71. ">Cohen 2009</a>; <a href="./references#CD005594-bbs2-0094" title="MoritaT , HiraiK , SakaguchiY , TsunetoS , ShimaY . Family‐perceived distress from delirium‐related symptoms of terminally ill cancer patients. Psychosomatics2004;45(2):107‐13. ">Morita 2004</a>; <a href="./references#CD005594-bbs2-0100" title="PartridgeJS , MartinFC , HarariD , DhesiJK . The delirium experience: what is the effect on patients, relatives and staff and what can be done to modify this?. International Journal of Geriatric Psychiatry2013;28(8):804‐12. ">Partridge 2013</a>). The economic burden of delirium is significant: a delirious state is associated with a 20% increased risk of prolonged hospitalisation, translating to an average of more than 8 to 10 additional days in hospital (<a href="./references#CD005594-bbs2-0084" title="LeslieDL , MarcantonioER , ZhangY , Leo‐SummersL , InouyeSK . One‐year health care costs associated with delirium in the elderly population. Archives of Internal Medicine2008;168(1):27‐32. ">Leslie 2008</a>; <a href="./references#CD005594-bbs2-0090" title="McCuskerJ , ColeM , DendukuriN , HanL , BelzileE . The course of delirium in older medical inpatients: a prospective study. Journal of General Internal Medicine2003;18(9):696‐704. ">McCusker 2003</a>; <a href="./references#CD005594-bbs2-0098" title="Organization for Economic Co‐operation and Development. OECD Health Data. www.oecd.org/health/ (accessed 3 December 2014). ">OECD 2012</a>; <a href="./references#CD005594-bbs2-0126" title="WHO Regional Office for Europe, World Health Organization. European hospital morbidity database. data.euro.who.int/hmdb/index.php (accessed 16 October 2014). ">WHO 2012</a>). The annual cost of delirium has been estimated at more than USD 164 billion (<a href="./references#CD005594-bbs2-0084" title="LeslieDL , MarcantonioER , ZhangY , Leo‐SummersL , InouyeSK . One‐year health care costs associated with delirium in the elderly population. Archives of Internal Medicine2008;168(1):27‐32. ">Leslie 2008</a>) in the United States, and over EUR 182 billion in 18 combined European countries (<a href="./references#CD005594-bbs2-0098" title="Organization for Economic Co‐operation and Development. OECD Health Data. www.oecd.org/health/ (accessed 3 December 2014). ">OECD 2012</a>; <a href="./references#CD005594-bbs2-0126" title="WHO Regional Office for Europe, World Health Organization. European hospital morbidity database. data.euro.who.int/hmdb/index.php (accessed 16 October 2014). ">WHO 2012</a>). Delirium in hospitalised patients clearly represents a substantial public health concern. </p> <p>Because of its myriad iatrogenic factors (e.g. medications, immobilisation, catheterisation, and sleep impairment) (<a href="./references#CD005594-bbs2-0073" title="InouyeSK , SchlesingerMJ , LydonTJ . Delirium: a symptom of how hospital care is failing older persons and a window to improve quality of hospital care. American Journal of Medicine1999;106(5):565‐73. ">Inouye 1999</a>), delirium is considered a preventable adverse event (<a href="./references#CD005594-bbs2-0059" title="GillickMR , SerrellNA , GillickLS . Adverse consequences of hospitalization in the elderly. Social Science and Medicine1982;16(10):1033‐8. ">Gillick 1982</a>; <a href="./references#CD005594-bbs2-0110" title="RothschildJM , BatesDW , LeapeLL . Preventable medical injuries in older patients. Archives of Internal Medicine2000;160(18):2717‐28. ">Rothschild 2000</a>) and is used as an indicator of quality of care in the elderly (<a href="./references#CD005594-bbs2-0069" title="Institute for Healthcare Improvement. Sedation, delirium, and mobility. www.ihi.org/Pages/default.aspx (accessed 3 February 2015). ">IHI 2014</a>; <a href="./references#CD005594-bbs2-0112" title="Safer Healthcare Now!. Prevention and management of delirium. www.saferhealthcarenow.ca/EN/Interventions/DeliriumPrevention/Pages/default.aspx (accessed 30 November 2014). ">Safer Healthcare Now 2005</a>). Notwithstanding, not all cases of delirium can be prevented and the impetus to determine safe and effective treatment strategies remains important for clinicians, patients, families, and the healthcare system. </p> <p>In clinical practice, antipsychotics are often the first pharmacological treatment initiated, despite conflicting evidence supporting their efficacy and reports indicating increased risk of serious adverse events, especially in the frail elderly (<a href="./references#CD005594-bbs2-0058" title="GillSS , BronskillSE , NormandSL , AndersonGM , SykoraK , LamK , et al. Antipsychotic drug use and mortality in older adults with dementia. Annals of Internal Medicine2007;146(11):775‐86. ">Gill 2007</a>; <a href="./references#CD005594-bbs2-0093" title="MittalV , KurupL , WilliamsonD , MuraleeS , TampiRR . Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. American Journal of Alzheimer's Disease and Other Dementias2011;26(1):10‐28. ">Mittal 2011</a>; <a href="./references#CD005594-bbs2-0104" title="RayWA , ChungCP , MurrayKT , HallK , SteinCM . Atypical antipsychotic drugs and the risk of sudden cardiac death. New England Journal of Medicine2009;360(3):225‐35. ">Ray 2009</a>; <a href="./references#CD005594-bbs2-0124" title="WangPS , SchneeweissS , AvornJ , FischerMA , MogunH , SolomonDH , et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. New England Journal of Medicine2005;353(22):2335‐41. ">Wang 2005</a>). Herein, we have updated the previously published Cochrane Review (<a href="./references#CD005594-bbs2-0129" title="LonerganE , BrittonAM , LuxenbergJ . Antipsychotics for delirium. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD005594.pub2] ">Lonergan 2007</a>). An update was warranted, given the high prevalence of hospital delirium, its associated clinical and financial burden, and the publication of new studies in the decade since the original publication. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD005594-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005594-sec-0042">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005594-sec-0143">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD005594-sec-0042"></div> <p>Our primary objective was to assess the efficacy of antipsychotics versus nonantipsychotics or placebo on the duration of delirium in hospitalised adults (excluding critically ill populations). </p> <p>Our secondary objectives were to compare the efficacy of 1) antipsychotics versus nonantipsychotics or placebo on a) delirium severity and b) delirium resolution, c) mortality, d) hospital length of stay, e) discharge disposition, f) health‐related quality of life, and g) adverse effects (e.g. sudden cardiac death, QTc prolongation (i.e. increased time between the Q wave and the end of the T wave in the heart's electrical cycle), seizures, use of physical restraints); and 2) atypical versus typical antipsychotics for reducing a) delirium duration, b) delirium severity, and c) resolution, d) mortality, e) hospital length of stay, f) discharge disposition, g) health‐related quality of life outcomes, and h) adverse effects (e.g. sudden cardiac death, QT prolongation, seizures, use of physical restraints). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD005594-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005594-sec-0043">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005594-sec-0144">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD005594-sec-0043"></div> <section id="CD005594-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD005594-sec-0045"> <h4 class="title">Types of studies</h4> <p>We included all trials using a randomised or quasi‐randomised design that compared an antipsychotic to a nonantipsychotic (e.g. alternative drug class such as benzodiazepines), placebo, or second antipsychotic of a different generation (secondary outcome) for the treatment of delirium. We excluded nonrandomised and cross‐over interventional studies as well as observational studies. </p> </section> <section id="CD005594-sec-0046"> <h4 class="title">Types of participants</h4> <p>We included studies of adults (&gt; 16 years of age) diagnosed with delirium and treated in an acute care setting. We excluded trials with a primary aim of treating delirium secondary to substance/alcohol‐induced withdrawal, recruiting participants solely in outpatient, psychiatric, or long‐term care settings, or in an intensive care unit (a high intensity unit). A delirium diagnosis had to have been made by a trained individual (e.g. psychiatrist, geriatrician), through formal assessment using Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria (<a href="./references#CD005594-bbs2-0050" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association, 1994. ">DSM‐IV 1994</a>; <a href="./references#CD005594-bbs2-0051" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington: American Psychiatric Association, 2000. ">DSM‐IV‐TR 2000</a>; <a href="./references#CD005594-bbs2-0052" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. Arlington: American Psychiatric Association, 2013. ">DSM‐V 2013</a>), or by a validated delirium screening tool (e.g. <a href="./references#CD005594-bbs2-0070" title="InouyeSK , VanDyckCH , AlessiCA , BalkinS , SiegalAP , HorwitzRI . Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Annals of Internal Medicine1990;113(12):941‐8. ">Inouye 1990</a>; <a href="./references#CD005594-bbs2-0095" title="NeelonVJ , ChampagneMT , CarlsonJR , FunkSG . The NEECHAM Confusion Scale: construction, validation, and clinical testing. Nursing Research1996;45(6):324‐30. ">Neelon 1996</a>; <a href="./references#CD005594-bbs2-0117" title="TraubeC , SilverG , KearneyJ , PatelA , AtkinsonTM , YoonMJ , et al. Cornell Assessment of Pediatric Delirium: a valid, rapid, observational tool for screening delirium in the PICU. Critical Care Medicine2014;42(3):656‐63. ">Traube 2014</a>). We excluded studies where antipsychotics were evaluated for delirium prevention. </p> </section> <section id="CD005594-sec-0047"> <h4 class="title">Types of interventions</h4> <p>To answer our primary objective, we included studies comparing an antipsychotic to a nonantipsychotic drug (e.g. alternative drug class such as benzodiazepine) or placebo. We permitted inclusion of trials that had a nonantipsychotic group without a placebo group, as no drug has been consistently shown to be more effective than placebo. Therefore, a nonantipsychotic group was thought of as a placebo. We also included studies comparing a typical antipsychotic to an atypical antipsychotic to answer our secondary objectives. When antipsychotics are initiated to manage delirium symptoms in clinical practice, clinicians often select atypical antipsychotics over a typical antipsychotic. Therefore, we included trials that compared the two classes of antipsychotics, irrespective of inclusion of a placebo group in the study. We did not include trials that only examined two or more antipsychotics of the same class without an alternative drug or alternative antipsychotic class, or placebo. </p> <p>A priori<i>,</i> we anticipated the selection of comparison treatments would be variable and that nonantipsychotic agents might include: alpha‐2 agonists, antidepressants, benzodiazepines, cholinesterase inhibitors, melatonin or melatonin agonists, or opioids. No restrictions on dose, frequency, intensity, or duration of therapy were applied. </p> </section> <section id="CD005594-sec-0048"> <h4 class="title">Types of outcome measures</h4> <p>We selected outcomes pertaining to the benefits and hazards of antipsychotic drugs that are meaningful to hospitalised patients with delirium, their families, and health care professionals. </p> <section id="CD005594-sec-0049"> <h5 class="title">Primary outcome</h5> <p> <ol id="CD005594-list-0001"> <li> <p>Total duration of delirium (days)</p> </li> </ol> </p> </section> <section id="CD005594-sec-0050"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD005594-list-0002"> <li> <p>Delirium severity, assessed by validated instruments such as Delirium Rating Scale (e.g. DRS or DRS‐98‐R) (<a href="./references#CD005594-bbs2-0118" title="TrzepaczPT , BakerRW , GreenhouseJ . A symptom rating scale for delirium. Psychiatry Research1988;23(1):89‐97. ">Trzepacz 1988</a>; <a href="./references#CD005594-bbs2-0121" title="TrzepaczPT , MittalD , TorresR , KanaryK , NortonJ , JimersonN . Validation of the Delirium Rating Scale‐revised‐98: comparison with the delirium rating scale and the cognitive test for delirium. Journal of Neuropsychiatry and Clinical Neurosciences2001;13(2):229‐42. ">Trzepacz 2001</a>) and Memorial Delirium Assessment Scale (MDAS) (<a href="./references#CD005594-bbs2-0034" title="BreitbartW , RosenfeldB , RothA , SmithMJ , CohenK , PassikS . The Memorial Delirium Assessment Scale. Journal of Pain and Symptom Management1997;13(3):128‐37. ">Breitbart 1997</a>) (mean change from baseline to end of study period) </p> </li> <li> <p>Delirium resolution (defined as reduction of DRS or DRS‐98‐R below a target set by the authors or complete resolution of symptoms) </p> </li> <li> <p>Mortality</p> </li> <li> <p>Hospital length of stay (days)</p> </li> <li> <p>Hospital discharge disposition (e.g. rehabilitation, chronic care facility, home)</p> </li> <li> <p>Health‐related quality of life (as reported by study authors)</p> </li> <li> <p>Adverse events as defined by the study authors (e.g. prolongation of the QTc interval (QT interval measures the time between the start of the Q wave and the end of the T wave in the heart’s electrical cycle), sudden cardiac death, cerebral vascular events, seizures, extrapyramidal effects, use of physical restraints, long‐term cognitive impairment (e.g. change in Mini Mental Status Exam or as reported by study authors)). </p> </li> </ol> </p> </section> </section> </section> <section id="CD005594-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD005594-sec-0052"> <h4 class="title">Electronic searches</h4> <p>Electronic search strategies were developed and tested through an iterative process by an experienced information scientist in consultation with our team. The concepts encompassed in the search strategy included: 1) population (i.e. patients in acute care settings diagnosed with delirium), 2) intervention (antipsychotics), and (3) comparators. Test searches were performed at various stages (i.e. before and after combining search terms) to ascertain the number of hits and verify capture of studies known to meet the inclusion criteria. We searched the following electronic databases from their respective dates of inception to July 20, 2017: MEDLINE (Ovid SP) (1946 to July 20, 2017); Embase (Ovid SP) (1947 to 2017 Week 28); Cochrane EBM Reviews ‐ Central Register of Controlled Trials (CENTRAL) (July 20, 2017); CINAHL (EBSCOhost) (1982 to July 20, 2017); Thomson Reuters Web of Science (July 20, 2017) and Latin American and Caribbean Health Sciences Literature (LILACS) (1986 to July 20, 2017). We searched the Database of Abstracts of Reviews of Effects (DARE) and the Health Technology Assessment Database (HTA Database) to their second quarter of 2017 for published reviews on the review topic. Specific details regarding search strategies can be found in the appendices (<a href="./appendices#CD005594-sec-0116">Appendix 1</a>; <a href="./appendices#CD005594-sec-0117">Appendix 2</a>; <a href="./appendices#CD005594-sec-0118">Appendix 3</a>; <a href="./appendices#CD005594-sec-0119">Appendix 4</a>; <a href="./appendices#CD005594-sec-0120">Appendix 5</a>; <a href="./appendices#CD005594-sec-0121">Appendix 6</a>; <a href="./appendices#CD005594-sec-0122">Appendix 7</a>; <a href="./appendices#CD005594-sec-0123">Appendix 8</a>). Search strategies utilised a combination of controlled vocabulary and keywords, and vocabulary and syntax were adjusted for each database. We limited our search to randomised controlled trials, systematic reviews, and meta‐analyses. We applied a filter to limit to humans, and no language restriction was imposed. </p> </section> <section id="CD005594-sec-0053"> <h4 class="title">Searching other resources</h4> <p>We searched conference proceedings using the Web of Science ISI Proceedings (2004 to July 2017). We searched for unpublished and ongoing trials on the following web sites: 1. www.clinicaltrials.gov/; and 2. www.who.int/trialsearch. We handsearched the reference lists of all retrieved studies for additional relevant studies. Corresponding authors of eligible trials and experts in the field were contacted to identify other potential studies. The Internet was searched using the Google search engine to find additional unpublished evidence. </p> </section> </section> <section id="CD005594-sec-0054"> <h3 class="title" id="CD005594-sec-0054">Data collection and analysis</h3> <section id="CD005594-sec-0055"> <h4 class="title">Selection of studies</h4> <p>Each title and abstract identified from the electronic and manual searches were independently examined by two authors (LB, LR) to identify potentially eligible trials. Selected trials were screened for relevance against defined inclusion and exclusion criteria (<a href="./appendices#CD005594-sec-0124">Appendix 9</a>). References were organised in the reference manager Endnote (Version X6, Thomson Reuters, Carlsbad, CA, USA) (<a href="./references#CD005594-bbs2-0054" title="Thomson Reuters. EndNote (Endnote Version X6). Calsbad, CA, USA: Thomson Reuters, 2012. ">Endnotes</a>) with reasons for exclusion documented in the notes field. The studies identified as eligible were examined independently and in full to confirm inclusion. Disagreements were resolved by discussion with an independent arbiter (NS). </p> </section> <section id="CD005594-sec-0056"> <h4 class="title">Data extraction and management</h4> <p>We did not blind data extractors to the identity of study authors because of our familiarity with the literature on the topic. Two authors (LB, LR) revised and piloted the previous data extraction form to ensure capture of all relevant data. Once the included trials were identified and agreed upon, four authors independently extracted data. Each study was independently examined by a pair of authors (SM and MP; JL and CB). All data extraction was confirmed by a third author (LB). Any identified duplicate reports from a single study were assembled as one reference. The 'Characteristics of included studies' table (<a href="./references#CD005594-sec-0134" title="">Characteristics of included studies</a>) was created using Review Manager (<a href="./references#CD005594-bbs2-0106" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> <p>As we were interested in determining if the intervention reduced the overall severity or burden of delirium, we extracted and used the highest recorded score for delirium severity for both the intervention and control arm when multiple time points were available. For example, if DRS‐98‐R was scored multiple times after study enrolment, then we selected only the highest of those scores for our analyses. </p> </section> <section id="CD005594-sec-0057"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Each data extractor independently assessed the risk of bias of each study, which was then verified by another author (NS). These assessments were done via a domain‐based evaluation as recommended by The Cochrane Collaboration (<a href="./references#CD005594-bbs2-0066" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). The domains are:<br/> 1. Random sequence generation (i.e. selection bias);<br/> 2. Allocation concealment (i.e. selection bias);<br/> 3. Blinding of participants and personnel (i.e. performance bias);<br/> 4. Blinding of outcomes assessment (i.e. detection bias);<br/> 5. Incomplete outcome data (i.e. attrition bias);<br/> 6. Selective reporting; and<br/> 7. Other potential sources of bias. </p> <p>For each domain, we assessed the risk of bias as 'low', 'high', or 'unclear'. Unclear risk was assigned if insufficient detail was reported, or if what happened in the study was known but the risk of bias was unclear or unknown. Once risk of bias assessment was agreed upon, each study was categorised as follows: </p> <p>Low risk of bias: studies where all domains were considered 'low' risk of bias;<br/> High risk of bias: studies where one or more domains were considered to be 'high' risk of bias; and<br/> Unclear risk of bias: studies where one or more domains was scored as 'unclear' risk of bias.<br/> We generated a 'risk of bias' graph figure and summary figure upon completion of assessment in Review Manager (<a href="./references#CD005594-bbs2-0106" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> </section> <section id="CD005594-sec-0058"> <h4 class="title">Measures of treatment effect</h4> <p>We used risk ratios (RRs) as measures of treatment effect for dichotomous outcomes. We used between‐group mean differences (MD or SMD) and standard deviations for continuous outcomes. </p> </section> <section id="CD005594-sec-0059"> <h4 class="title">Unit of analysis issues</h4> <p>We used data from individual participants as the unit of analysis in each trial arm. As anticipated, all included trials were parallel group design, so adjustments were not necessary for clustering. </p> </section> <section id="CD005594-sec-0060"> <h4 class="title">Dealing with missing data</h4> <p>When necessary, we contacted the corresponding authors to clarify issues related to data reporting and/or to obtain further study details. Missing data and dropout rates were assessed for each included study and reported in the risk of bias table. For missing data (e.g. standard deviations associated with continuous outcomes) we sent the corresponding author a maximum of three emails to request the missing information. If this failed, we used established methods to impute standard deviation values. When only medians and interquartile ranges (IQR) or ranges were reported and not available from study authors we assumed the median value to be equal to the mean to permit utilisation of all of data identified. To estimate standard deviations we used 'IQR/1.35' or 'range/4' (for studies with n &lt; 70) and 'range/6' for studies with n &gt; 70. </p> </section> <section id="CD005594-sec-0061"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity can be the result of an uneven distribution of important clinical and methodological effect modifiers across studies or across comparisons. We assessed each trial for statistical and clinical heterogeneity. We evaluated statistical heterogeneity using the I² statistic and the X² test of homogeneity with p &lt; 0.05 indicative of heterogeneity. We applied the categorisation values described by Higgins: low (0% to 40%), moderate (30% to 60%), substantial (50% to 90%), and considerable (75% to 100%) heterogeneity (<a href="./references#CD005594-bbs2-0065" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). We qualitatively assessed clinical heterogeneity by examining delirium management strategies in each trial (e.g. treatment dose, use of rescue medications or chemical restraint when primary treatment fails, non‐drug treatment strategies such as noise reduction or improving the day‐night cycle, medications avoided, physical restraint) as well as country of study origin, year of study publication, and single centre versus multicentre study. </p> </section> <section id="CD005594-sec-0062"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned construction and visual inspection of funnel plots to assess for possible publication bias in Review Manager 5 (<a href="./references#CD005594-bbs2-0106" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) for analyses where &gt; 10 studies were available. We planned to test for funnel plot asymmetry using the test proposed by Egger (<a href="./references#CD005594-bbs2-0053" title="EggerM , SmithGD , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315:629‐34. ">Egger 1997</a>), but there were insufficient studies to proceed with this step. </p> </section> <section id="CD005594-sec-0063"> <h4 class="title">Data synthesis</h4> <p>Two authors (LB, BH) entered data in Revman 5 (<a href="./references#CD005594-bbs2-0106" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). Three authors (LB, BH, DF) conducted the analyses and reported summary statistics for the data. We synthesised dichotomous data with risk ratios (RR) and 95% confidence intervals (CI) using the Mantel‐Haenszel random‐effects model (REM) to allow for adjustments that incorporated variation both within and between studies (<a href="./references#CD005594-bbs2-0048" title="DeMetsDL . Methods for combining randomized clinical trials. Statistics in Medicine1987;6(3):341‐50. ">DeMets 1987</a>). Continuous outcomes (e.g. duration of delirium, hospital length of stay) were synthesised as pooled mean differences (MD), or standardised mean differences (SMD) (where measurement scales varied across studies) with 95% CIs using random‐effects inverse variance methods. For continuous end points that involved an analysis of changes from baseline in each group, where necessary, a correlation coefficient was used to estimate the standard deviation associated with mean change in each group. We considered P &lt; 0.05 (two sided) as significant. </p> </section> <section id="CD005594-sec-0064"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned the following subgroup analyses to determine if the efficacy and safety of antipsychotics were influenced by: 1) age (&lt; 65 versus ≥ 65 years); and 2) history of dementia. </p> </section> <section id="CD005594-sec-0065"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses to explore the effect on the pooled estimate of including only studies at low risk of bias in all but one domain and those that included a placebo group. </p> <section id="CD005594-sec-0066"> <h5 class="title">Data presentation ‐ 'Summary of findings' table</h5> <p>We used the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) (<a href="./references#CD005594-bbs2-0062" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. ">Guyatt 2008</a>) approach to assess the quality of the supporting evidence associated with selected outcomes. The findings are presented using a 'Summary of findings' (SoF) table summarising the amount of data identified, within‐study risk of bias, directness of evidence, data heterogeneity, and precision of effect estimates. The SoF table was generated using GRADEpro software (<a href="./references#CD005594-bbs2-0061" title="EvidencePrime , Inc . GRADEpro Guideline Development Tool. Version (accessed prior to 17 May 2018). Hamilton (ON): McMaster University, 2015. [gradepro.org] ">GRADEpro GDT 2015</a>). We selected the following outcomes a priori as being relevant for clinical practice: duration of delirium, severity of delirium, delirium resolution, mortality, hospital length of stay, and incidence of adverse effects. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD005594-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD005594-sec-0067"></div> <section id="CD005594-sec-0068"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD005594-sec-0134" title="">Characteristics of included studies</a>; <a href="./references#CD005594-sec-0135" title="">Characteristics of excluded studies</a>; <a href="./references#CD005594-sec-0136" title="">Characteristics of studies awaiting classification</a>; <a href="./references#CD005594-sec-0137" title="">Characteristics of ongoing studies</a> </p> <p>We included randomised and quasi‐randomised controlled trials of adult hospitalised non‐ICU patients treated for delirium. We identified eligible trials with an intervention arm including an antipsychotic drug. Delirium management for control arms included a nonantipsychotic drug (e.g. alternative drug class such as benzodiazepines), placebo, or secondary antipsychotic of alternative class (i.e. typical versus atypical). </p> <section id="CD005594-sec-0069"> <h4 class="title">Results of the search</h4> <p>We reported the results of the search outlined above in <a href="#CD005594-fig-0001">Figure 1</a>. The initial electronic database query yielded 21,599 citations. We retrieved 132 references for full‐text assessment. We identified nine studies meeting inclusion criteria, and excluded the remaining 123. We classified four studies as awaiting classification (<a href="./references#CD005594-sec-0136" title="">Characteristics of studies awaiting classification</a>): one full publication (<a href="./references#CD005594-bbs2-0028" title="NakamuraJ , UchimuraN , YamadaS , NakazawaY . Does plasma free‐3‐methoxy‐4‐hydroxyphenyl(ethylene)glycol increase in the delirious state? A comparison of the effects of mianserin and haloperidol on delirium. International Clinical Psychopharmacology1997;12(3):147‐52. ">Nakamura 1997</a>) and three conference abstracts (<a href="./references#CD005594-bbs2-0025" title="DjokicG , ZivkovicN , PavicevicD , et al. Risperidone vs. haloperidol in treatment of delirium superimposed on dementia. European Neuropsychopharmacology2008;18 Suppl 4:S504‐5. ">Djokic 2008</a>; <a href="./references#CD005594-bbs2-0026" title="Jung JinK , Hyun KookL , Chi UnP , Chang UkL , In HoP , ChulL . Comparison of intramuscular olanzapine and haloperidol for the treatment of delirium. European Psychiatry2009;24:S1006. ">Jung Jin 2009</a>; <a href="./references#CD005594-bbs2-0027" title="LeeJ . Comparison of efficacy and side effects between aripiprazole and haloperidol in the treatment of delirium. International Psychogeriatrics2013;1:S132‐3. ">Lee 2013</a>). We identified two trial registrations for further consideration. We classified one study as meeting inclusion criteria and ongoing (<a href="./references#CD005594-bbs2-0029" title="NCT02345902 . Treatment of hypoactive delirium and outcome measures. clinicaltrials.gov/ct2/show/NCT02345902?term=NCT02345902&amp;rank=1 (first received 26 January 2015). ">NCT02345902</a>; <a href="./references#CD005594-sec-0137" title="">Characteristics of ongoing studies</a>), and the other as a duplicate of a study published in full and already included in the review (<a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>; <a href="./references#CD005594-sec-0134" title="">Characteristics of included studies</a>). When this latter study was translated into the English language, the primary author's first and last names were reversed. We identified this upon closer inspection and classified the second trial registration as a duplicate. </p> <div class="figure" id="CD005594-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow diagram of search results." data-id="CD005594-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram of search results.</p> </div> </div> </div> </section> <section id="CD005594-sec-0070"> <h4 class="title">Included studies</h4> <p>See: <a href="./references#CD005594-sec-0134" title="">Characteristics of included studies</a> table. </p> <p>We included nine randomised trials with a total of 727 participants (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>; <a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a>; <a href="./references#CD005594-bbs2-0003" title="GroverS , KumarV , ChakrabartiS . Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research2011;71(4):277‐81. ">Grover 2011</a>; <a href="./references#CD005594-bbs2-0004" title="GroverS , MahajanS , ChakrabartiS , AvasthiA . Comparative effectiveness of quetiapine and haloperidol in delirium: a single blind randomized controlled study. World Journal of Psychiatry2016;6(3):365‐71. ">Grover 2016</a>; <a href="./references#CD005594-bbs2-0005" title="HanCS , KimYK . A double‐blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics2004;45(4):297‐301. ">Han 2004</a>; <a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>; <a href="./references#CD005594-bbs2-0007" title="LinCJ , SunFJ , FangCK , ChenHW , LaiYL . An open trial comparing haloperidol with olanzapine for the treatment of delirium in palliative and hospice center cancer patients. Journal of Internal Medicine of Taiwan2008;19:346‐54. ">Lin 2008</a>; <a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>; <a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>). We provide detailed descriptions of each study in the <a href="./references#CD005594-sec-0134" title="">Characteristics of included studies</a> table. Sample sizes of trials ranged from 24 (<a href="./references#CD005594-bbs2-0005" title="HanCS , KimYK . A double‐blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics2004;45(4):297‐301. ">Han 2004</a>) to 247 (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>) participants. Four of the identified trials included more than two study arms (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>; <a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a>; <a href="./references#CD005594-bbs2-0003" title="GroverS , KumarV , ChakrabartiS . Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research2011;71(4):277‐81. ">Grover 2011</a>; <a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>). Only a single study (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>) included multiple sites; all others had a single centre design. The trials were conducted in a number of countries: Australia (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>); China (<a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>); India (<a href="./references#CD005594-bbs2-0003" title="GroverS , KumarV , ChakrabartiS . Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research2011;71(4):277‐81. ">Grover 2011</a>; <a href="./references#CD005594-bbs2-0004" title="GroverS , MahajanS , ChakrabartiS , AvasthiA . Comparative effectiveness of quetiapine and haloperidol in delirium: a single blind randomized controlled study. World Journal of Psychiatry2016;6(3):365‐71. ">Grover 2016</a>); Korea (<a href="./references#CD005594-bbs2-0005" title="HanCS , KimYK . A double‐blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics2004;45(4):297‐301. ">Han 2004</a>); Taiwan (<a href="./references#CD005594-bbs2-0007" title="LinCJ , SunFJ , FangCK , ChenHW , LaiYL . An open trial comparing haloperidol with olanzapine for the treatment of delirium in palliative and hospice center cancer patients. Journal of Internal Medicine of Taiwan2008;19:346‐54. ">Lin 2008</a>); Thailand (<a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>); United States (<a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a>); and United Kingdom (<a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>). All studies included hospitalised patient populations: medical only (<a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a>; <a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>; <a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>), mixed medical and surgical (<a href="./references#CD005594-bbs2-0003" title="GroverS , KumarV , ChakrabartiS . Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research2011;71(4):277‐81. ">Grover 2011</a>; <a href="./references#CD005594-bbs2-0004" title="GroverS , MahajanS , ChakrabartiS , AvasthiA . Comparative effectiveness of quetiapine and haloperidol in delirium: a single blind randomized controlled study. World Journal of Psychiatry2016;6(3):365‐71. ">Grover 2016</a>; <a href="./references#CD005594-bbs2-0005" title="HanCS , KimYK . A double‐blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics2004;45(4):297‐301. ">Han 2004</a>; <a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>), and palliative (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>; <a href="./references#CD005594-bbs2-0007" title="LinCJ , SunFJ , FangCK , ChenHW , LaiYL . An open trial comparing haloperidol with olanzapine for the treatment of delirium in palliative and hospice center cancer patients. Journal of Internal Medicine of Taiwan2008;19:346‐54. ">Lin 2008</a>). One trial specifically evaluated participants with dementia (<a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>). The mean reported age of participants across trials ranged from 44 (<a href="./references#CD005594-bbs2-0003" title="GroverS , KumarV , ChakrabartiS . Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research2011;71(4):277‐81. ">Grover 2011</a>) to 84 (<a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>) years; 22% (<a href="./references#CD005594-bbs2-0004" title="GroverS , MahajanS , ChakrabartiS , AvasthiA . Comparative effectiveness of quetiapine and haloperidol in delirium: a single blind randomized controlled study. World Journal of Psychiatry2016;6(3):365‐71. ">Grover 2016</a>) to 71% (<a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>) of participants were female. Six studies (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>; <a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a>; <a href="./references#CD005594-bbs2-0003" title="GroverS , KumarV , ChakrabartiS . Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research2011;71(4):277‐81. ">Grover 2011</a>; <a href="./references#CD005594-bbs2-0005" title="HanCS , KimYK . A double‐blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics2004;45(4):297‐301. ">Han 2004</a>; <a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>; <a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>) provided details of funding sources; one trial received pharmaceutical industry funding (<a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>). </p> <p>Four trials compared one or more antipsychotic drug to a nonantipsychotic or placebo (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>; <a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a>; <a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>; <a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>), three of these trials included a placebo group (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>; <a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>; <a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>), and one compared antipsychotics (haloperidol or chlorpromazine) to the benzodiazepine lorazepam (<a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a>). Seven trials compared a typical to an atypical antipsychotic drug (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>; <a href="./references#CD005594-bbs2-0003" title="GroverS , KumarV , ChakrabartiS . Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research2011;71(4):277‐81. ">Grover 2011</a>; <a href="./references#CD005594-bbs2-0004" title="GroverS , MahajanS , ChakrabartiS , AvasthiA . Comparative effectiveness of quetiapine and haloperidol in delirium: a single blind randomized controlled study. World Journal of Psychiatry2016;6(3):365‐71. ">Grover 2016</a>; <a href="./references#CD005594-bbs2-0005" title="HanCS , KimYK . A double‐blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics2004;45(4):297‐301. ">Han 2004</a>; <a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>; <a href="./references#CD005594-bbs2-0007" title="LinCJ , SunFJ , FangCK , ChenHW , LaiYL . An open trial comparing haloperidol with olanzapine for the treatment of delirium in palliative and hospice center cancer patients. Journal of Internal Medicine of Taiwan2008;19:346‐54. ">Lin 2008</a>; <a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>). Of these, two (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>; <a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>) also included a placebo group (i.e. 3‐arm studies). </p> <p>Haloperidol was the most commonly studied antipsychotic, evaluated in all but one trial (<a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>). All trials titrated study drug based on symptom response. The duration of therapy was variable and included three‐ (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>), six‐ (<a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a>; <a href="./references#CD005594-bbs2-0003" title="GroverS , KumarV , ChakrabartiS . Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research2011;71(4):277‐81. ">Grover 2011</a>; <a href="./references#CD005594-bbs2-0004" title="GroverS , MahajanS , ChakrabartiS , AvasthiA . Comparative effectiveness of quetiapine and haloperidol in delirium: a single blind randomized controlled study. World Journal of Psychiatry2016;6(3):365‐71. ">Grover 2016</a>), seven‐ (<a href="./references#CD005594-bbs2-0005" title="HanCS , KimYK . A double‐blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics2004;45(4):297‐301. ">Han 2004</a>; <a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>; <a href="./references#CD005594-bbs2-0007" title="LinCJ , SunFJ , FangCK , ChenHW , LaiYL . An open trial comparing haloperidol with olanzapine for the treatment of delirium in palliative and hospice center cancer patients. Journal of Internal Medicine of Taiwan2008;19:346‐54. ">Lin 2008</a>; <a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>), and ten‐day (<a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>) administration. The use of rescue drugs such as benzodiazepines for breakthrough agitation was permitted in five trials (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>; <a href="./references#CD005594-bbs2-0003" title="GroverS , KumarV , ChakrabartiS . Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research2011;71(4):277‐81. ">Grover 2011</a>; <a href="./references#CD005594-bbs2-0004" title="GroverS , MahajanS , ChakrabartiS , AvasthiA . Comparative effectiveness of quetiapine and haloperidol in delirium: a single blind randomized controlled study. World Journal of Psychiatry2016;6(3):365‐71. ">Grover 2016</a>; <a href="./references#CD005594-bbs2-0007" title="LinCJ , SunFJ , FangCK , ChenHW , LaiYL . An open trial comparing haloperidol with olanzapine for the treatment of delirium in palliative and hospice center cancer patients. Journal of Internal Medicine of Taiwan2008;19:346‐54. ">Lin 2008</a>; <a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>), prohibited in three (<a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>; <a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>; <a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a>), and not reported in one (<a href="./references#CD005594-bbs2-0005" title="HanCS , KimYK . A double‐blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics2004;45(4):297‐301. ">Han 2004</a>). No trial reported on the use of physical restraints or sitters/personal attendants. </p> <p>All trials used some combination of DSM criteria (<a href="./references#CD005594-bbs2-0050" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association, 1994. ">DSM‐IV 1994</a>; <a href="./references#CD005594-bbs2-0051" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington: American Psychiatric Association, 2000. ">DSM‐IV‐TR 2000</a>; <a href="./references#CD005594-bbs2-0052" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. Arlington: American Psychiatric Association, 2013. ">DSM‐V 2013</a>) or the Confusion Assessment Method (CAM) (<a href="./references#CD005594-bbs2-0070" title="InouyeSK , VanDyckCH , AlessiCA , BalkinS , SiegalAP , HorwitzRI . Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Annals of Internal Medicine1990;113(12):941‐8. ">Inouye 1990</a>), or both, to detect delirium for study enrolment; subjects in all included studies were screened daily. Cointerventions for delirium management such as reorientation, family support, and environmental manipulations were used in five studies (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>; <a href="./references#CD005594-bbs2-0003" title="GroverS , KumarV , ChakrabartiS . Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research2011;71(4):277‐81. ">Grover 2011</a>; <a href="./references#CD005594-bbs2-0004" title="GroverS , MahajanS , ChakrabartiS , AvasthiA . Comparative effectiveness of quetiapine and haloperidol in delirium: a single blind randomized controlled study. World Journal of Psychiatry2016;6(3):365‐71. ">Grover 2016;</a><a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>; <a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>) and not reported in the remaining four (<a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a>; <a href="./references#CD005594-bbs2-0005" title="HanCS , KimYK . A double‐blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics2004;45(4):297‐301. ">Han 2004</a>; <a href="./references#CD005594-bbs2-0007" title="LinCJ , SunFJ , FangCK , ChenHW , LaiYL . An open trial comparing haloperidol with olanzapine for the treatment of delirium in palliative and hospice center cancer patients. Journal of Internal Medicine of Taiwan2008;19:346‐54. ">Lin 2008</a>; <a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>). </p> </section> <section id="CD005594-sec-0071"> <h4 class="title">Excluded studies</h4> <p>See: <a href="./references#CD005594-sec-0135" title="">Characteristics of excluded studies</a> table. </p> <p>We excluded ten randomised trials because the population of interest was limited to critically ill individuals (<a href="./references#CD005594-bbs2-0010" title="Al‐QadheebNS , SkrobikY , SchumakerG , PachecoMN , RobertsRJ , RuthazerRR , et al. Randomized ICU trials do not demonstrate an association between interventions that reduce delirium duration and short‐term mortality: a systematic review and meta‐analysis. Critical Care Medicine2014;42(6):1442‐54. ">Al Qadheeb 2016</a>; <a href="./references#CD005594-bbs2-0011" title="AtalanN , SevimME , AkgunS , FazligullariO , BasaranC . Morphine is a reasonable alternative to haloperidol in the treatment of postoperative hyperactive‐type delirium after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2013;27(5):933‐8. ">Atalan 2013</a>; <a href="./references#CD005594-bbs2-0012" title="BakriMH , IsmailEA , IbrahimA . Comparison of dexmedetomidine or ondansetron with haloperidol for treatment of postoperative delirium in trauma patients admitted to intensive care unit: randomized controlled trial. Anaesthesia, Pain &amp; Intensive Care2015;19(2):118‐23. ">Bakri 2015</a>; <a href="./references#CD005594-bbs2-0013" title="DevlinJW , RobertRJ , FongJJ , SkrobikY , RikerRR , HillNS , et al. Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double‐blind, placebo‐controlled pilot study. Critical Care Medicine2010;38(2):419‐27. ">Devlin 2010</a>; <a href="./references#CD005594-bbs2-0014" title="GirardTD , PandharipandePP , CarsonSS , SchmidtGA , WrightPE , CanonicoAE , et al. Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: the MIND randomized, placebo‐controlled trial. Critical Care Medicine2010;38(2):428‐37. ">Girard 2010</a>; <a href="./references#CD005594-bbs2-0015" title="HakimSM , OthmanAI , NaoumDO . Early treatment with risperidone for subsyndromal delirium after on‐pump cardiac surgery in the elderly: a randomized trial. Anesthesiology2012;116(5):987‐97. ">Hakim 2012</a>; <a href="./references#CD005594-bbs2-0020" title="PageVJ , ElyEW , GatesS , ZhaoXB , AlceT , ShintaniA , et al. Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope‐ICU): a randomised, double‐blind, placebo‐controlled trial. Lancet Respiratory Medicine2013;1(7):515‐23. ">Page 2013</a>; <a href="./references#CD005594-bbs2-0021" title="ReadeMC , O'SullivanK , BatesS , GoldsmithD , AinslieWRTSJ , BellomoR . Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open‐label trial. Critical Care2009;13(3):R75. ">Reade 2009</a>; <a href="./references#CD005594-bbs2-0022" title="ReadeMC , EastwoodGM , BellomoR , BaileyM , BerstenA , CheungB , et al. Effect of dexmedetomidine added to standard care on ventilator‐free time in patients with agitated delirium: a randomized clinical trial. JAMA2016;315(14):1460‐8. ">Reade 2016</a>; <a href="./references#CD005594-bbs2-0024" title="SkrobikY , BergeronN , DumontM , GottfriedSB . Olanzapine vs haloperidol: treating delirium in a critical care setting. Intensive Care Medicine2004;30(3):444‐9. ">Skrobik 2014</a>). These trials are included in the Cochrane protocol ACE311 'Pharmacological interventions for the treatment of delirium in critically ill patients' (<a href="./references#CD005594-bbs2-0040" title="BurryL , MehtaS , WilliamsonDR , HuttonB , ElyEW , AdhikariNKJ , et al. Pharmacological interventions for the treatment of delirium in critically ill patients. Cochrane Database of Systematic Reviews of Interventions2015, Issue 6. [DOI: 10.1002/14651858.CD011749] ">Burry 2015</a>) using the operational definition of critical care/intensive care applied by this Cochrane division. We excluded five additional studies (<a href="./references#CD005594-bbs2-0016" title="JungSW , KimKS . A randomized controlled, pilot study of aripiprazole in the treatment of delirium. European Neuropsychopharmacology2009;19(Supp 3):S553–4. ">Jung 2009</a>; <a href="./references#CD005594-bbs2-0017" title="JungSW , SakongJK , LeeJY , ChoiYR , SuhHS . Comparison between effectiveness of quetiapine and risperidone for treatment of delirium in hospitalized patients. International Journal of Neuropsychopharmacology2010;13:96. ">Jung 2010</a>; <a href="./references#CD005594-bbs2-0018" title="KimSW , YooJA , LeeSY , KimSY , BaeKY , YangSJ , et al. Risperidone versus olanzapine for the treatment of patients with delirium. Human Psychopharmacology2010;25(4):298‐302. ">Kim 2010</a>; <a href="./references#CD005594-bbs2-0019" title="LeeKU , WonWY , LeeHK , KweonYS , LeeCT , PaeCU , et al. Amisulpride versus quetiapine for the treatment of delirium: a randomized, open prospective study. International Clinical Psychopharmacology2005;20(6):e311‐e314. ">Lee 2005</a>; <a href="./references#CD005594-bbs2-0023" title="SakongJK , JungSW , KimJS , KooBH . Comparison between effectiveness of aripiprazole and risperidone for treatment of delirium in hospitalized patients. European Neuropsychopharmacology2010;20:S568‐9. ">Sakong 2010</a>) because of lack of adequate comparator group. These five studies evaluated the effect of antipsychotic(s) on hospitalised, non‐critically ill participants with delirium but did not include a nonantipsychotic arm or they compared two antipsychotics of the same class (e.g. atypical versus atypical) without a third group that included a placebo or nonantipsychotic drug. </p> </section> </section> <section id="CD005594-sec-0072"> <h3 class="title">Risk of bias in included studies</h3> <p>The 'Risk of bias' tables present details on the performance of the included trials for each risk of bias domain. A summary of our judgement of the methodological quality of the included studies is depicted in <a href="#CD005594-fig-0002">Figure 2</a> and <a href="#CD005594-fig-0003">Figure 3</a>. Only one study (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>) was scored as low risk of bias across all domains. The remaining studies scored unclear risk of bias in one or more domains, or had a combination of unclear and high risk of bias across multiple domains. In particular, <a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a> scored high risk of bias across two domains.. </p> <div class="figure" id="CD005594-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD005594-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD005594-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD005594-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD005594-sec-0073"> <h4 class="title">Allocation (selection bias):</h4> <p>Five studies (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>; <a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a>; <a href="./references#CD005594-bbs2-0004" title="GroverS , MahajanS , ChakrabartiS , AvasthiA . Comparative effectiveness of quetiapine and haloperidol in delirium: a single blind randomized controlled study. World Journal of Psychiatry2016;6(3):365‐71. ">Grover 2016</a>; <a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>; <a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>) specified the use of randomisation tables. The method of sequence generation was not reported in the manuscript or available from the authors for the remaining four trials (<a href="./references#CD005594-bbs2-0003" title="GroverS , KumarV , ChakrabartiS . Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research2011;71(4):277‐81. ">Grover 2011</a>; <a href="./references#CD005594-bbs2-0005" title="HanCS , KimYK . A double‐blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics2004;45(4):297‐301. ">Han 2004</a>; <a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>; <a href="./references#CD005594-bbs2-0007" title="LinCJ , SunFJ , FangCK , ChenHW , LaiYL . An open trial comparing haloperidol with olanzapine for the treatment of delirium in palliative and hospice center cancer patients. Journal of Internal Medicine of Taiwan2008;19:346‐54. ">Lin 2008</a>), therefore, we scored these as unclear risk of bias. </p> <p>We judged five studies (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>; <a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a>; <a href="./references#CD005594-bbs2-0003" title="GroverS , KumarV , ChakrabartiS . Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research2011;71(4):277‐81. ">Grover 2011</a>; <a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>; <a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>) to have low risk of selection bias based on their allocation concealment measures. Two studies (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>; <a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>) used sealed opaque envelopes and another used a pharmacist (<a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a>) not otherwise involved in patient care to dispense the study drug. In <a href="./references#CD005594-bbs2-0003" title="GroverS , KumarV , ChakrabartiS . Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research2011;71(4):277‐81. ">Grover 2011</a>, the randomisation and study drug dose adjustments were carried out by one investigator who did not assess outcomes. In <a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>, identical capsules were used to dispense the study drug. We judged the remaining studies (<a href="./references#CD005594-bbs2-0004" title="GroverS , MahajanS , ChakrabartiS , AvasthiA . Comparative effectiveness of quetiapine and haloperidol in delirium: a single blind randomized controlled study. World Journal of Psychiatry2016;6(3):365‐71. ">Grover 2016</a>; <a href="./references#CD005594-bbs2-0005" title="HanCS , KimYK . A double‐blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics2004;45(4):297‐301. ">Han 2004</a>; <a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>; <a href="./references#CD005594-bbs2-0007" title="LinCJ , SunFJ , FangCK , ChenHW , LaiYL . An open trial comparing haloperidol with olanzapine for the treatment of delirium in palliative and hospice center cancer patients. Journal of Internal Medicine of Taiwan2008;19:346‐54. ">Lin 2008</a>) to have unclear risk of selection bias due to insufficient or no detail to assess allocation concealment. </p> </section> <section id="CD005594-sec-0074"> <h4 class="title">Blinding (performance bias and detection bias):</h4> <p>We judged all studies but one (<a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>) to have low risk of blinding bias. Four studies (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>; <a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a>; <a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>; <a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>) were double‐blinded. A single‐blind design was used in three studies (<a href="./references#CD005594-bbs2-0003" title="GroverS , KumarV , ChakrabartiS . Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research2011;71(4):277‐81. ">Grover 2011</a>; <a href="./references#CD005594-bbs2-0004" title="GroverS , MahajanS , ChakrabartiS , AvasthiA . Comparative effectiveness of quetiapine and haloperidol in delirium: a single blind randomized controlled study. World Journal of Psychiatry2016;6(3):365‐71. ">Grover 2016</a>; <a href="./references#CD005594-bbs2-0007" title="LinCJ , SunFJ , FangCK , ChenHW , LaiYL . An open trial comparing haloperidol with olanzapine for the treatment of delirium in palliative and hospice center cancer patients. Journal of Internal Medicine of Taiwan2008;19:346‐54. ">Lin 2008</a>) that specifically reported the delirium assessment was performed by a standard blinded assessor. Although <a href="./references#CD005594-bbs2-0005" title="HanCS , KimYK . A double‐blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics2004;45(4):297‐301. ">Han 2004</a> study was stated as double‐blind, this was unlikely as the study drugs were not stated to be identical. However, one psychiatrist, blind to treatment group, performed the delirium assessments. We judged <a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a> study to have high risk of bias as it was not possible to blind subcutaneous haloperidol and enteral olanzapine, unless a double‐dummy design was used. As no details were provided, we assumed the drug formulation was unblinded. </p> </section> <section id="CD005594-sec-0075"> <h4 class="title">Incomplete outcome data (attrition bias):</h4> <p>We judged three studies (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>; <a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>; <a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>) to have low risk of attrition bias because all used intention‐to‐treat analysis or had no missing data. We judged one study (<a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a>) to have unclear risk of attrition bias. The lorazepam arm in <a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a> was discontinued early due to adverse events, but available data were used in the analysis. We judged five studies (<a href="./references#CD005594-bbs2-0003" title="GroverS , KumarV , ChakrabartiS . Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research2011;71(4):277‐81. ">Grover 2011</a>; <a href="./references#CD005594-bbs2-0004" title="GroverS , MahajanS , ChakrabartiS , AvasthiA . Comparative effectiveness of quetiapine and haloperidol in delirium: a single blind randomized controlled study. World Journal of Psychiatry2016;6(3):365‐71. ">Grover 2016</a>; <a href="./references#CD005594-bbs2-0005" title="HanCS , KimYK . A double‐blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics2004;45(4):297‐301. ">Han 2004</a>; <a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>; <a href="./references#CD005594-bbs2-0007" title="LinCJ , SunFJ , FangCK , ChenHW , LaiYL . An open trial comparing haloperidol with olanzapine for the treatment of delirium in palliative and hospice center cancer patients. Journal of Internal Medicine of Taiwan2008;19:346‐54. ">Lin 2008</a>) to have high risk of attrition bias due to incomplete data or missing participants. In <a href="./references#CD005594-bbs2-0003" title="GroverS , KumarV , ChakrabartiS . Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research2011;71(4):277‐81. ">Grover 2011</a>, ten participants did not complete the study; six could not be assessed at least once due to worsening clinical status, and four left hospital against medical advice. In <a href="./references#CD005594-bbs2-0004" title="GroverS , MahajanS , ChakrabartiS , AvasthiA . Comparative effectiveness of quetiapine and haloperidol in delirium: a single blind randomized controlled study. World Journal of Psychiatry2016;6(3):365‐71. ">Grover 2016</a>, seven participants did not complete the study; four could not be assessed because they left against medical advice, one quetiapine participant received injectable haloperidol for symptom management, and two could not be started on the study drug because of worsening clinical status. In the <a href="./references#CD005594-bbs2-0005" title="HanCS , KimYK . A double‐blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics2004;45(4):297‐301. ">Han 2004</a> study, four participants did not complete the study, three due to medical complications and one due to spousal refusal; these participants were not included in the analysis. The <a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a> study made no mention of how attrition was factored into the statistical analysis despite reporting five participants not completing the study (one death, one leaving due to financial reasons, one discharge, and two withdrawals). Lastly, <a href="./references#CD005594-bbs2-0007" title="LinCJ , SunFJ , FangCK , ChenHW , LaiYL . An open trial comparing haloperidol with olanzapine for the treatment of delirium in palliative and hospice center cancer patients. Journal of Internal Medicine of Taiwan2008;19:346‐54. ">Lin 2008</a> did not report the total number of participants enrolled or lost to follow‐up. </p> </section> <section id="CD005594-sec-0076"> <h4 class="title">Selective reporting (reporting bias):</h4> <p>We found four trials were registered (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>; <a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>; <a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>; <a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>) and, therefore, it was possible to examine reporting bias. These trials were deemed at low risk of bias. For the remaining studies, we scored them as at unclear risk of bias. </p> </section> <section id="CD005594-sec-0077"> <h4 class="title">Other potential sources of bias:</h4> <p>Referral bias was a potential issue for four trials (<a href="./references#CD005594-bbs2-0003" title="GroverS , KumarV , ChakrabartiS . Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research2011;71(4):277‐81. ">Grover 2011</a>; <a href="./references#CD005594-bbs2-0004" title="GroverS , MahajanS , ChakrabartiS , AvasthiA . Comparative effectiveness of quetiapine and haloperidol in delirium: a single blind randomized controlled study. World Journal of Psychiatry2016;6(3):365‐71. ">Grover 2016</a>; <a href="./references#CD005594-bbs2-0007" title="LinCJ , SunFJ , FangCK , ChenHW , LaiYL . An open trial comparing haloperidol with olanzapine for the treatment of delirium in palliative and hospice center cancer patients. Journal of Internal Medicine of Taiwan2008;19:346‐54. ">Lin 2008</a>; <a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>) where participants were recruited specifically from referrals to psychiatry services. Sample size calculations were not provided for five trials (<a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a>; <a href="./references#CD005594-bbs2-0003" title="GroverS , KumarV , ChakrabartiS . Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research2011;71(4):277‐81. ">Grover 2011</a>; <a href="./references#CD005594-bbs2-0004" title="GroverS , MahajanS , ChakrabartiS , AvasthiA . Comparative effectiveness of quetiapine and haloperidol in delirium: a single blind randomized controlled study. World Journal of Psychiatry2016;6(3):365‐71. ">Grover 2016</a>; <a href="./references#CD005594-bbs2-0005" title="HanCS , KimYK . A double‐blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics2004;45(4):297‐301. ">Han 2004</a>; <a href="./references#CD005594-bbs2-0007" title="LinCJ , SunFJ , FangCK , ChenHW , LaiYL . An open trial comparing haloperidol with olanzapine for the treatment of delirium in palliative and hospice center cancer patients. Journal of Internal Medicine of Taiwan2008;19:346‐54. ">Lin 2008</a>) so it was unclear if adequate power was attained. Two trials (<a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>; <a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>) did not meet the required sample size. In one study (<a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>), 34 participants per group were needed to have adequate power to detect a meaningful difference in DRS‐R‐98 score; however, the final numbers were 24 and 28 participants in the quetiapine and haloperidol groups, respectively. The sample size calculation was reported in the second study (<a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>), however the trial was stopped early at the request of the manufacturer due to the FDA's concern on the use of antipsychotic medication in the elderly. The study was therefore underpowered. Finally, one included study (<a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>) permitted lorazepam injection for rescue, but all participants who received it were in the quetiapine group. It was unclear how lorazepam administration in only one group would influence results. </p> </section> </section> <section id="CD005594-sec-0078"> <h3 class="title" id="CD005594-sec-0078">Effects of interventions</h3> <p>See: <a href="./full#CD005594-tbl-0001"><b>Summary of findings for the main comparison</b> Antipsychotics versus nonantipsychotics or placebo for the treatment of delirium in hospitalised patients</a>; <a href="./full#CD005594-tbl-0002"><b>Summary of findings 2</b> Typical versus atypical antipsychotics for treatment of delirium in hospitalised patients</a> </p> <p>See: <a href="./full#CD005594-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD005594-tbl-0002">summary of findings Table 2</a> </p> <p>We present below our analyses for our primary outcome, duration of delirium, and our secondary outcomes of severity of delirium, delirium resolution, mortality, hospital length of stay and discharge disposition, health‐related quality of life, and adverse events. For each outcome, we present first the results for the comparison of an antipsychotic versus nonantipsychotic or placebo and then the class comparison of typical versus atypical antipsychotic. </p> <section id="CD005594-sec-0079"> <h4 class="title">Duration of delirium</h4> <section id="CD005594-sec-0080"> <h5 class="title">Antipsychotic versus nonantipsychotic drug or placebo</h5> <p>Duration of delirium was not reported for any of the four trials comparing an antipsychotic to a nonantipsychotic drug. </p> </section> <section id="CD005594-sec-0081"> <h5 class="title">Typical versus atypical antipsychotic drug</h5> <p>Duration of delirium was not reported for any trial comparing typical versus atypical antipsychotics drugs. </p> </section> </section> <section id="CD005594-sec-0082"> <h4 class="title">Delirium severity</h4> <section id="CD005594-sec-0083"> <h5 class="title">Antipsychotic versus nonantipsychotic drug or placebo</h5> <p>Delirium severity was reported for four studies (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>; <a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a>; <a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>; <a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>). Delirium severity was scored with different tools: the DRS (<a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a>; <a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>), DRS‐98‐R (<a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>), and MDAS (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>), assessed at baseline and at the end of the study. Three of the studies were double‐blind so delirium assessments were blinded. The pooled result indicated no difference in delirium severity (SMD ‐1.08, 95% CI ‐2.55 to 0.39; four studies; 494 participants; <a href="./references#CD005594-fig-0012" title="">Analysis 1.1</a>; <a href="#CD005594-fig-0004">Figure 4</a>). There was substantial heterogeneity (I² = 97%). We assessed this as very low‐quality evidence (downgraded due to risk of bias, inconsistency and imprecision). For sensitivity analyses, we repeated the analysis by i) removing trial(s) that did not have a placebo group (<a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a>) (SMD ‐0.89, 95% CI ‐2.64 to 0.86; three studies; 464 participants; I² = 98%; <a href="./references#CD005594-fig-0013" title="">Analysis 1.2</a>) and ii) including only trials with low risk of bias (SMD 0.03, 95% CI ‐0.22 to 0.27; 289 participants; I² = 0%; <a href="./references#CD005594-fig-0014" title="">Analysis 1.3</a>). </p> <div class="figure" id="CD005594-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 severity of delirium, outcome: 2.1 antipsychotic versus no antipsychotic." data-id="CD005594-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 severity of delirium, outcome: 2.1 antipsychotic versus no antipsychotic. </p> </div> </div> </div> </section> <section id="CD005594-sec-0084"> <h5 class="title">Typical versus atypical antipsychotic drug</h5> <p>Seven studies (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>; <a href="./references#CD005594-bbs2-0003" title="GroverS , KumarV , ChakrabartiS . Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research2011;71(4):277‐81. ">Grover 2011</a>; <a href="./references#CD005594-bbs2-0004" title="GroverS , MahajanS , ChakrabartiS , AvasthiA . Comparative effectiveness of quetiapine and haloperidol in delirium: a single blind randomized controlled study. World Journal of Psychiatry2016;6(3):365‐71. ">Grover 2016</a>; <a href="./references#CD005594-bbs2-0005" title="HanCS , KimYK . A double‐blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics2004;45(4):297‐301. ">Han 2004</a>; <a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>; <a href="./references#CD005594-bbs2-0007" title="LinCJ , SunFJ , FangCK , ChenHW , LaiYL . An open trial comparing haloperidol with olanzapine for the treatment of delirium in palliative and hospice center cancer patients. Journal of Internal Medicine of Taiwan2008;19:346‐54. ">Lin 2008</a>; <a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>) reported this outcome. All but one trial (<a href="./references#CD005594-bbs2-0005" title="HanCS , KimYK . A double‐blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics2004;45(4):297‐301. ">Han 2004</a>) had delirium assessment by a psychiatrist or nurse blinded to the status of treatment. Delirium severity was scored with the DRS (<a href="./references#CD005594-bbs2-0005" title="HanCS , KimYK . A double‐blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics2004;45(4):297‐301. ">Han 2004</a>; <a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>; <a href="./references#CD005594-bbs2-0007" title="LinCJ , SunFJ , FangCK , ChenHW , LaiYL . An open trial comparing haloperidol with olanzapine for the treatment of delirium in palliative and hospice center cancer patients. Journal of Internal Medicine of Taiwan2008;19:346‐54. ">Lin 2008</a>), DRS‐98‐R (<a href="./references#CD005594-bbs2-0003" title="GroverS , KumarV , ChakrabartiS . Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research2011;71(4):277‐81. ">Grover 2011</a>; <a href="./references#CD005594-bbs2-0004" title="GroverS , MahajanS , ChakrabartiS , AvasthiA . Comparative effectiveness of quetiapine and haloperidol in delirium: a single blind randomized controlled study. World Journal of Psychiatry2016;6(3):365‐71. ">Grover 2016</a>; <a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>) and MDAS (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>), assessed at baseline and at the end of study treatment. The pooled result showed no difference in delirium severity (SMD ‐0.17, 95% CI ‐0.37 to 0.02; 542 participants, <a href="./references#CD005594-fig-0015" title="">Analysis 1.4</a>; <a href="#CD005594-fig-0005">Figure 5</a>). There was a low degree of heterogeneity (I² = 16%). We assessed this as low‐quality evidence (downgraded due to risk of bias, inconsistency). It was not feasible to conduct the sensitivity analysis including only trials at low risk of bias. </p> <div class="figure" id="CD005594-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 severity of delirium, outcome: 1.4 atypical antipsychotic versus typical antipsychotic." data-id="CD005594-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 severity of delirium, outcome: 1.4 atypical antipsychotic versus typical antipsychotic. </p> </div> </div> </div> </section> </section> <section id="CD005594-sec-0085"> <h4 class="title">Delirium resolution</h4> <section id="CD005594-sec-0086"> <h5 class="title">Antipsychotic versus nonantipsychotic drug or placebo</h5> <p>Delirium resolution was reported for three studies (<a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a>; <a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>; <a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>). The definition of resolution applied in the trials varied: complete alleviation of symptoms (<a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>), alleviation of symptoms to below an unspecified diagnostic threshold (<a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a>), and a cutoff of DRS‐R98 &lt; 15 on day 7 (<a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>). Two of the studies were double‐blind so delirium assessments were blinded. The pooled result indicated no significant difference in overall delirium resolution (RR 0.95, 95% CI 0.30 to 2.98; three studies, 247 participants; <a href="./references#CD005594-fig-0016" title="">Analysis 2.1</a>; <a href="#CD005594-fig-0006">Figure 6</a>). There was a high degree of heterogeneity (I² = 83%). We assessed this as very low‐quality evidence (downgraded due to risk of bias, inconsistency, imprecision). As a sensitivity analysis, we (<a href="./references#CD005594-fig-0017" title="">Analysis 2.2</a>) included only trials with a placebo group (<a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>; <a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>). The pooled result indicated no significant difference in overall delirium resolution (RR 1.43, 95% CI 0.58 to 3.54; two studies; 217 participants) but with less heterogeneity (I² = 30%). It was not feasible to conduct the sensitivity analysis including only trials at low risk of bias. </p> <div class="figure" id="CD005594-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 resolution, outcome: 3.1 antipsychotic versus no antipsychotic." data-id="CD005594-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 resolution, outcome: 3.1 antipsychotic versus no antipsychotic.</p> </div> </div> </div> </section> <section id="CD005594-sec-0087"> <h5 class="title">Typical versus atypical antipsychotic drug</h5> <p>Delirium resolution was reported for five studies (<a href="./references#CD005594-bbs2-0003" title="GroverS , KumarV , ChakrabartiS . Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research2011;71(4):277‐81. ">Grover 2011</a>; <a href="./references#CD005594-bbs2-0004" title="GroverS , MahajanS , ChakrabartiS , AvasthiA . Comparative effectiveness of quetiapine and haloperidol in delirium: a single blind randomized controlled study. World Journal of Psychiatry2016;6(3):365‐71. ">Grover 2016</a>; <a href="./references#CD005594-bbs2-0005" title="HanCS , KimYK . A double‐blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics2004;45(4):297‐301. ">Han 2004</a>; <a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>; <a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>). The definition of resolution varied in the trials: DRS‐R98 &lt; 10 (<a href="./references#CD005594-bbs2-0003" title="GroverS , KumarV , ChakrabartiS . Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research2011;71(4):277‐81. ">Grover 2011</a>; <a href="./references#CD005594-bbs2-0004" title="GroverS , MahajanS , ChakrabartiS , AvasthiA . Comparative effectiveness of quetiapine and haloperidol in delirium: a single blind randomized controlled study. World Journal of Psychiatry2016;6(3):365‐71. ">Grover 2016</a>), DRS‐R98 &lt; 12 (<a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>), MDAS &lt; 13 (<a href="./references#CD005594-bbs2-0005" title="HanCS , KimYK . A double‐blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics2004;45(4):297‐301. ">Han 2004</a>), and complete alleviation of symptoms (<a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>). Four of the trials (<a href="./references#CD005594-bbs2-0003" title="GroverS , KumarV , ChakrabartiS . Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research2011;71(4):277‐81. ">Grover 2011</a>; <a href="./references#CD005594-bbs2-0004" title="GroverS , MahajanS , ChakrabartiS , AvasthiA . Comparative effectiveness of quetiapine and haloperidol in delirium: a single blind randomized controlled study. World Journal of Psychiatry2016;6(3):365‐71. ">Grover 2016</a>; <a href="./references#CD005594-bbs2-0005" title="HanCS , KimYK . A double‐blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics2004;45(4):297‐301. ">Han 2004</a>; <a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>) were blinded studies and had blinded delirium assessments. The pooled result indicated no significant difference in overall delirium resolution (RR 1.10, 95% CI 0.79 to 1.52; 349 participants; <a href="./references#CD005594-fig-0018" title="">Analysis 2.3</a>; <a href="#CD005594-fig-0007">Figure 7</a>). There was a low degree of heterogeneity (I² = 2%). We assessed this as low‐quality evidence (downgraded due to risk of bias, inconsistency). It was not feasible to conduct the sensitivity analysis including only trials at low risk of bias. </p> <div class="figure" id="CD005594-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 resolution, outcome: 2.3 atypical antipsychotic versus typical antipsychotic." data-id="CD005594-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 resolution, outcome: 2.3 atypical antipsychotic versus typical antipsychotic. </p> </div> </div> </div> </section> </section> <section id="CD005594-sec-0088"> <h4 class="title">Mortality</h4> <section id="CD005594-sec-0089"> <h5 class="title">Antipsychotic versus nonantipsychotic drug or placebo</h5> <p>Mortality was reported for three studies (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>; <a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a>; <a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>). The end point was measured at study day three (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>), within one week of study completion (<a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a>), and at day 30 (<a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>). The pooled result indicated no statistical difference in mortality (RR 1.29, 95% CI 0.73 to 2.27; three studies, 319 participants; <a href="./references#CD005594-fig-0019" title="">Analysis 3.1</a>; <a href="#CD005594-fig-0008">Figure 8</a>). There was a low degree of heterogeneity (I² = 0%). We assessed this as low‐quality evidence (downgraded due to risk of bias, imprecision). We conducted a sensitivity analysis with only trials that included a placebo group (<a href="./references#CD005594-fig-0020" title="">Analysis 3.2</a>). The pooled result indicated no statistical difference in mortality (RR 1.41, 95% CI 0.75 to 2.66; two studies; 289 participants; I² = 0%). </p> <div class="figure" id="CD005594-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 mortality, outcome: 3.1 antipsychotic versus no antipsychotic." data-id="CD005594-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 mortality, outcome: 3.1 antipsychotic versus no antipsychotic.</p> </div> </div> </div> </section> <section id="CD005594-sec-0090"> <h5 class="title">Typical versus atypical antipsychotic drug</h5> <p>Mortality was reported for four studies (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>; <a href="./references#CD005594-bbs2-0003" title="GroverS , KumarV , ChakrabartiS . Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research2011;71(4):277‐81. ">Grover 2011</a>; <a href="./references#CD005594-bbs2-0004" title="GroverS , MahajanS , ChakrabartiS , AvasthiA . Comparative effectiveness of quetiapine and haloperidol in delirium: a single blind randomized controlled study. World Journal of Psychiatry2016;6(3):365‐71. ">Grover 2016</a>; <a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>). Time to end point was measured at study day three (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>) and within one week of study enrolment (<a href="./references#CD005594-bbs2-0003" title="GroverS , KumarV , ChakrabartiS . Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research2011;71(4):277‐81. ">Grover 2011</a>; <a href="./references#CD005594-bbs2-0004" title="GroverS , MahajanS , ChakrabartiS , AvasthiA . Comparative effectiveness of quetiapine and haloperidol in delirium: a single blind randomized controlled study. World Journal of Psychiatry2016;6(3):365‐71. ">Grover 2016</a>; <a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>). Mortality was very low and no deaths were reported in two studies (<a href="./references#CD005594-bbs2-0003" title="GroverS , KumarV , ChakrabartiS . Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research2011;71(4):277‐81. ">Grover 2011</a>; <a href="./references#CD005594-bbs2-0004" title="GroverS , MahajanS , ChakrabartiS , AvasthiA . Comparative effectiveness of quetiapine and haloperidol in delirium: a single blind randomized controlled study. World Journal of Psychiatry2016;6(3):365‐71. ">Grover 2016</a>). The pooled result indicated no statistical difference in overall mortality (RR 1.71, 95% CI 0.82 to 3.35; four studies; 342 participants; <a href="./references#CD005594-fig-0021" title="">Analysis 3.3</a>; <a href="#CD005594-fig-0009">Figure 9</a>). There was a low degree of heterogeneity (I² = 0%). We assessed this as low‐quality evidence (downgraded due to risk of bias, imprecision). </p> <div class="figure" id="CD005594-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 mortality, outcome: 3.3 atypical antipsychotic versus typical antipsychotic." data-id="CD005594-fig-0009" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 mortality, outcome: 3.3 atypical antipsychotic versus typical antipsychotic. </p> </div> </div> </div> </section> </section> <section id="CD005594-sec-0091"> <h4 class="title">Hospital length of stay (days)</h4> <section id="CD005594-sec-0092"> <h5 class="title">Antipsychotic versus nonantipsychotic drug or placebo</h5> <p>No trials reported hospital length of stay, and attempts to obtain data from corresponding study authors proved unsuccessful. </p> </section> <section id="CD005594-sec-0093"> <h5 class="title">Typical versus atypical antipsychotic drug</h5> <p>No trials reported hospital length of stay, and attempts to obtain data from corresponding study authors proved unsuccessful. </p> </section> </section> <section id="CD005594-sec-0094"> <h4 class="title">Hospital discharge disposition</h4> <section id="CD005594-sec-0095"> <h5 class="title">Antipsychotic versus nonantipsychotic drug or placebo</h5> <p>No trials reported hospital discharge disposition, and attempts to obtain data from corresponding study authors proved unsuccessful. </p> </section> <section id="CD005594-sec-0096"> <h5 class="title">Typical versus atypical antipsychotic drug</h5> <p>No trials reported hospital discharge disposition, and attempts to obtain data from corresponding study authors proved unsuccessful. </p> </section> </section> <section id="CD005594-sec-0097"> <h4 class="title">Health‐related quality of life</h4> <section id="CD005594-sec-0098"> <h5 class="title">Antipsychotic versus nonantipsychotic drug or placebo</h5> <p>No trials reported health‐related quality of life, and attempts to obtain data from corresponding study authors proved unsuccessful. </p> </section> <section id="CD005594-sec-0099"> <h5 class="title">Typical versus atypical antipsychotic drug</h5> <p>No trials reported health‐related quality of life and attempts to obtain data from corresponding study authors proved unsuccessful. </p> </section> </section> <section id="CD005594-sec-0100"> <h4 class="title">Adverse events</h4> <section id="CD005594-sec-0101"> <h5 class="title">Antipsychotic versus nonantipsychotic drug or placebo</h5> <p>No trials reported the use of physical restraints, long‐term cognitive measures, or incidence of seizures, cerebrovascular events, sudden cardiac death or QTc abnormalities. Extrapyramidal symptoms (EPS) were reported for three studies (<a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a>; <a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>; <a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>). EPS was assessed using the Extrapyramidal Symptom Rating Scale in two trials (<a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a>; <a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>), and the method was not reported in the other trial (<a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>). The overall number of reported EPS events was low in the trials. The pooled result indicated the risk of EPS with antipsychotics was not statistically increased (RR 1.70, 95% CI 0.04 to 65.57; 247 participants; <a href="./references#CD005594-fig-0022" title="">Analysis 4.1</a>; <a href="#CD005594-fig-0010">Figure 10</a>). There was substantial heterogeneity (I² = 77%). We assessed the evidence as very low‐quality evidence (downgraded due to risk of bias, inconsistency, imprecision). One additional study (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>) reported significantly greater mean extrapyramidal effects in risperidone versus placebo‐treated participants using mixed effects modelling, without specifying the actual summary measure used (0.73, 95% CI 0.09 to 1.37, P = 0.03) and haloperidol versus placebo‐treated (0.79, 95% CI 0.17 to 1.41, P = 0.01) participants on each study day. Raw data were not available, thus, we were unable to pool these data with the other trials. </p> <div class="figure" id="CD005594-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 4 adverse event, outcome: 4.1 antipsychotic versus no antipsychotic (EPS)." data-id="CD005594-fig-0010" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 4 adverse event, outcome: 4.1 antipsychotic versus no antipsychotic (EPS). </p> </div> </div> </div> </section> <section id="CD005594-sec-0102"> <h5 class="title">Typical versus atypical antipsychotic drug</h5> <p>No trials reported the use of physical restraints, long‐term cognitive measures, cerebrovascular events, sudden cardiac death or QTc abnormalities. One trial (<a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>) reported on seizures with one seizure in the quetiapine group and no seizures in the haloperidol group. This trial also reported arrhythmias with one AV block episode in the haloperidol group and no events in the quetiapine group. Two trials (<a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>; <a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>) reported EPS symptoms. EPS was assessed using the Extrapyramidal Symptom Rating Scale in one trial (<a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>) and the other with MSAS (<a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>). The overall number of participants experiencing any EPS symptoms was low. The pooled results showed no statistical increased risk of EPS with typical antipsychotics compared to atypical antipsychotics (RR 12.16, 95% CI 0.55 to 269.52; two studies; 198 participants; <a href="./references#CD005594-fig-0023" title="">Analysis 4.2</a>; <a href="#CD005594-fig-0011">Figure 11</a>). There was a moderate degree of heterogeneity (I² = 54%). We assessed the evidence as very low‐quality evidence (downgraded due to risk of bias, inconsistency, imprecision). </p> <div class="figure" id="CD005594-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 4 adverse event, outcome: 4.2 atypical antipsychotic versus typical antipsychotic (EPS)." data-id="CD005594-fig-0011" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 4 adverse event, outcome: 4.2 atypical antipsychotic versus typical antipsychotic (EPS). </p> </div> </div> </div> </section> </section> <section id="CD005594-sec-0103"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We intended to conduct subgroup analyses exploring the effects of controlling for age and history of dementia. However, due to the small number of included studies and lack of relevant data, these analyses could not be conducted. We found substantial heterogeneity in analysis 1.1 (<a href="./references#CD005594-fig-0012" title="">Analysis 1.1</a>), 1.2 (<a href="./references#CD005594-fig-0013" title="">Analysis 1.2</a>) and 4.1 (<a href="./references#CD005594-fig-0022" title="">Analysis 4.1</a>). When we removed the studies not at low risk of bias (<a href="./references#CD005594-bbs2-0002" title="BreitbartW , MarottaR , PlattMM , WeismanH , DerevencoM , GrauC , et al. A double‐blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry1996;153(2):231‐7. ">Breitbart 1996</a> and <a href="./references#CD005594-bbs2-0006" title="HuH , DengW , YangH . A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal2004;8(7):1234‐7. ">Hu 2004</a>; <a href="./references#CD005594-fig-0014" title="">Analysis 1.3</a>) there is no longer such variability. We believe the use of different tools to measure the outcome may potentially explain the variation identified. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD005594-sec-0104" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005594-sec-0104">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005594-sec-0168">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD005594-sec-0104"></div> <section id="CD005594-sec-0105"> <h3 class="title" id="CD005594-sec-0105">Summary of main results</h3> <p>We identified nine randomised trials evaluating antipsychotics for treatment of delirium in hospitalised, non‐ICU patients. Four of the trials compared antipsychotics to nonantipsychotic drugs or placebo and seven compared typical to atypical antipsychotics. We found no evidence for determining the effect of antipsychotic drugs (as a class or by type) on duration of delirium. The current evidence does not support the use of an antipsychotic drug to reduce delirium severity, shorten time to resolution, or reduce mortality. We found no evidence to determine the effect of antipsychotics on length of hospital stay or health‐related quality of life. Low‐quality evidence showed adverse drug events were infrequently assessed but available data indicated extrapyramidal side effects were not more common with antipsychotic drugs compared to nonantipsychotic drugs or placebo and typical antipsychotics (e.g. haloperidol) were comparable to atypical antipsychotics (e.g. risperidone). </p> </section> <section id="CD005594-sec-0106"> <h3 class="title" id="CD005594-sec-0106">Overall completeness and applicability of evidence</h3> <p>The original version of this Cochrane Review included three trials (<a href="./references#CD005594-bbs2-0129" title="LonerganE , BrittonAM , LuxenbergJ . Antipsychotics for delirium. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD005594.pub2] ">Lonergan 2007</a>). We had anticipated finding a large number of new trials investigating antipsychotics for a number of reasons, including the known association between delirium and adverse patient outcomes, that delirium is deemed publicly important and is an indicator of quality of care in the elderly, and the fact that the 2010 NICE guidelines recommended further research. Despite the ten‐year time lapse since the original version of this review, the body of evidence for treatment of delirium for hospitalised non‐ICU patients with antipsychotic drugs remains limited and fraught with issues. Although we identified nine trials for inclusion, none of the trials reported on delirium duration, length of hospital stay, hospital discharge destination, health‐related quality of life, and many of the adverse events we perceived were important to patients, families and clinicians. Most of the studies were single centre studies with insufficient sample size, heterogeneous study populations, and at risk of bias. Only one trial was an adequately powered trial that included a placebo group (<a href="./references#CD005594-bbs2-0001" title="AgarM , LawlorP , QuinnS , DraperB , CaplanG , RowettD , et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine2016;177(1):34‐42. ">Agar 2016</a>) with low risk of bias across all domains. It is also important to note there were differences in how some of the outcomes were measured in the trials. For example, there were sufficient studies to pool for the outcomes, delirium severity and resolution of symptoms, but different tools were used and the time points assessed were not consistent. Our planned subgroup analyses to determine if there were differences in effect/safety in the older or dementia participant populations could not be addressed because of lack of data. We had anticipated finding more evidence in these populations as delirium is common in these subgroups. </p> </section> <section id="CD005594-sec-0107"> <h3 class="title" id="CD005594-sec-0107">Quality of the evidence</h3> <p>We scored the risk of bias for each trial and used GRADEpro software to inform the generation of evidence quality statements. Of the nine randomised controlled trials included in this review, only one trial scored low risk of bias across all domains. Although this review included only randomised controlled trials, the quality of evidence was downgraded for risk of bias, inconsistency, or imprecision. There were some notable design issues of these trials that should be factored into future trials. Guidelines suggest antipsychotics only be considered once non‐drug strategies are considered ineffective or insufficient for the distressed patient. Only half of the identified trials reported that non‐drug strategies were used during the study period and details of the interventions applied were not provided. Also, the use of rescue therapies for agitation, such as benzodiazepines, was not consistently reported. Physical restraint use was not reported in any trial. Use of chemical and physical restraint as rescue therapy presents an opportunity to introduce bias and thus should be standardised and reported in future trials. There was heterogeneity for some outcomes and their measurement methods. For the outcomes, severity and resolution of delirium, variable tools were used, different definitions or thresholds were applied, and the outcomes were assessed at different time points. In future trials, one must also consider the fact that delirium severity rating scales tend to focus more on hyperactive delirium, which is less common, rather than hypoactive delirium. </p> </section> <section id="CD005594-sec-0108"> <h3 class="title" id="CD005594-sec-0108">Potential biases in the review process</h3> <p>This review followed the Cochrane procedures and there were only a small number of amendments to the review process (outlined in <a href="#CD005594-sec-0132">Differences between protocol and review</a>). </p> </section> <section id="CD005594-sec-0109"> <h3 class="title" id="CD005594-sec-0109">Agreement and disagreements with other studies or reviews</h3> <p>The original version of this Cochrane Review did not answer the specific question of the effect of antipsychotics compared to no antipsychotics on delirium outcomes in hospitalised non‐ICU patients. We believe it is critical to first understand if antipsychotics as a class are effective and safe for management of delirium before comparing typical and atypical antipsychotics. We have expanded on the original review to answer this specific question before comparing typical and atypical antipsychotics. On the advice of Cochrane, we also narrowed the population by excluding the clinically unique critically ill patient population. </p> <p>Our principal finding was consistent with a recent comprehensive review by Neufeld and colleagues (<a href="./references#CD005594-bbs2-0096" title="NeufeldKJ , YueJ , RobinsonTN , InouyeSK , NeedhamDM . Antipsychotic medication for prevention and treatment of delirium in hospitalized adults: a systematic review and meta‐analysis. Journal of the American Geriatrics Society2016;64(4):705‐14. ">Neufeld 2016</a>). Neufeld and colleagues did not find the available evidence supported antipsychotic use for prevention or treatment of delirium in any hospitalised patient population. This review included studies of any design (prospective or historical cohort, case‐control, and other observational designs) and they included both ICU and non‐ICU participant populations. The generated outcomes were based on nearly all trials enrolling only critically ill participants. Kirshi and colleagues (<a href="./references#CD005594-bbs2-0081" title="KishiT , HirotaT , MatsunagaS , IwataN . Antipsychotic medications for the treatment of delirium: a systematic review and meta‐analysis of randomised controlled trials. J Neurology, Neurosurgery, &amp; Psychiatry2016;87:767‐74. ">Kishi 2016</a>) similarly conducted a systematic review to examine antipsychotics for treatment of delirium. The review also included both ICU and non‐ICU participant populations in 15 studies. Four of the studies included were unpublished or in abstract form only; these were excluded from our review as well as the Neufeld review. The primary outcomes measure for Kirshi's review was response rate at the study end point, examining many different severity and global scales. They found antipsychotics were superior to placebo or nonantipsychotic drugs in this analysis of ICU and non‐ICU studies in terms of response rate (RR 0.22, 95% CI 0.15 to 0.34, P &lt; 0.00001, I² = 0%, three studies). When they performed a subgroup analysis using only ICU studies they found the pooled result was marginally superior to placebo or nonantipsychotic drugs (RR 0.25, 95% CI 0.06 to 1.02, p = 0.05, N = 1); using only non‐ICU studies the result was the same as the pooled ICU and non‐ICU studies with antipsychotics significantly superior to no antipsychotic (RR 0.22, 95% CI 0.15 to 0.34, P &lt; 0.00001, I² = 0%, two studies). Similarly for the analysis of delirium severity, antipsychotics were significantly superior to no antipsychotic (SMD ‐1.27, 95% CI ‐2.44 to ‐0.11, P = 0.03, I<sup>2</sup> = 93%, two studies). For these analyses, we included two additional trials. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD005594-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/urn:x-wiley:14651858:media:CD005594:CD005594-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_t/tCD005594-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram of search results." data-id="CD005594-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow diagram of search results.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/full#CD005594-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005594-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/urn:x-wiley:14651858:media:CD005594:CD005594-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_t/tCD005594-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD005594-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/full#CD005594-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005594-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/urn:x-wiley:14651858:media:CD005594:CD005594-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_t/tCD005594-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD005594-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/full#CD005594-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005594-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/urn:x-wiley:14651858:media:CD005594:CD005594-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_t/tCD005594-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 severity of delirium, outcome: 2.1 antipsychotic versus no antipsychotic." data-id="CD005594-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 severity of delirium, outcome: 2.1 antipsychotic versus no antipsychotic. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/full#CD005594-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005594-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/urn:x-wiley:14651858:media:CD005594:CD005594-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_t/tCD005594-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 severity of delirium, outcome: 1.4 atypical antipsychotic versus typical antipsychotic." data-id="CD005594-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 severity of delirium, outcome: 1.4 atypical antipsychotic versus typical antipsychotic. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/full#CD005594-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005594-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/urn:x-wiley:14651858:media:CD005594:CD005594-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_t/tCD005594-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 resolution, outcome: 3.1 antipsychotic versus no antipsychotic." data-id="CD005594-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 resolution, outcome: 3.1 antipsychotic versus no antipsychotic.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/full#CD005594-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005594-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/urn:x-wiley:14651858:media:CD005594:CD005594-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_t/tCD005594-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 resolution, outcome: 2.3 atypical antipsychotic versus typical antipsychotic." data-id="CD005594-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 resolution, outcome: 2.3 atypical antipsychotic versus typical antipsychotic. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/full#CD005594-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005594-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/urn:x-wiley:14651858:media:CD005594:CD005594-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_t/tCD005594-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 mortality, outcome: 3.1 antipsychotic versus no antipsychotic." data-id="CD005594-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 mortality, outcome: 3.1 antipsychotic versus no antipsychotic.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/full#CD005594-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005594-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/urn:x-wiley:14651858:media:CD005594:CD005594-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_t/tCD005594-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 mortality, outcome: 3.3 atypical antipsychotic versus typical antipsychotic." data-id="CD005594-fig-0009" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 mortality, outcome: 3.3 atypical antipsychotic versus typical antipsychotic. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/full#CD005594-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005594-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/urn:x-wiley:14651858:media:CD005594:CD005594-AFig-FIG10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_t/tCD005594-AFig-FIG10.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 4 adverse event, outcome: 4.1 antipsychotic versus no antipsychotic (EPS)." data-id="CD005594-fig-0010" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Forest plot of comparison: 4 adverse event, outcome: 4.1 antipsychotic versus no antipsychotic (EPS). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/full#CD005594-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005594-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/urn:x-wiley:14651858:media:CD005594:CD005594-AFig-FIG11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_t/tCD005594-AFig-FIG11.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 4 adverse event, outcome: 4.2 atypical antipsychotic versus typical antipsychotic (EPS)." data-id="CD005594-fig-0011" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Forest plot of comparison: 4 adverse event, outcome: 4.2 atypical antipsychotic versus typical antipsychotic (EPS). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/full#CD005594-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-AFig-FIG11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005594-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/urn:x-wiley:14651858:media:CD005594:CD005594-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_t/tCD005594-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Severity of delirium, Outcome 1 Antipsychotic versus no antipsychotic." data-id="CD005594-fig-0012" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Severity of delirium, Outcome 1 Antipsychotic versus no antipsychotic.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/references#CD005594-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005594-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/urn:x-wiley:14651858:media:CD005594:CD005594-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_t/tCD005594-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Severity of delirium, Outcome 2 Sensitivity analysis (placebo‐controlled studies only)." data-id="CD005594-fig-0013" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Severity of delirium, Outcome 2 Sensitivity analysis (placebo‐controlled studies only). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/references#CD005594-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005594-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/urn:x-wiley:14651858:media:CD005594:CD005594-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_t/tCD005594-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Severity of delirium, Outcome 3 Sensitivity analysis (trials at low risk of bias)." data-id="CD005594-fig-0014" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Severity of delirium, Outcome 3 Sensitivity analysis (trials at low risk of bias). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/references#CD005594-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005594-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/urn:x-wiley:14651858:media:CD005594:CD005594-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_t/tCD005594-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Severity of delirium, Outcome 4 Typical versus atypical antipsychotic." data-id="CD005594-fig-0015" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Severity of delirium, Outcome 4 Typical versus atypical antipsychotic.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/references#CD005594-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005594-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/urn:x-wiley:14651858:media:CD005594:CD005594-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_t/tCD005594-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Resolution, Outcome 1 Antipsychotic versus no antipsychotic." data-id="CD005594-fig-0016" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Resolution, Outcome 1 Antipsychotic versus no antipsychotic.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/references#CD005594-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005594-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/urn:x-wiley:14651858:media:CD005594:CD005594-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_t/tCD005594-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Resolution, Outcome 2 Sensitivity analysis (including placebo studies)." data-id="CD005594-fig-0017" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Resolution, Outcome 2 Sensitivity analysis (including placebo studies).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/references#CD005594-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005594-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/urn:x-wiley:14651858:media:CD005594:CD005594-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_t/tCD005594-CMP-002-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Resolution, Outcome 3 Resolution (atypical versus typical antipsychotic)." data-id="CD005594-fig-0018" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Resolution, Outcome 3 Resolution (atypical versus typical antipsychotic).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/references#CD005594-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005594-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/urn:x-wiley:14651858:media:CD005594:CD005594-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_t/tCD005594-CMP-003-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Mortality, Outcome 1 Mortality (antipsychotic versus no antipsychotic)." data-id="CD005594-fig-0019" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Mortality, Outcome 1 Mortality (antipsychotic versus no antipsychotic).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/references#CD005594-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005594-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/urn:x-wiley:14651858:media:CD005594:CD005594-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_t/tCD005594-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Mortality, Outcome 2 Sensitivity analysis (including only placebo studies)." data-id="CD005594-fig-0020" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Mortality, Outcome 2 Sensitivity analysis (including only placebo studies).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/references#CD005594-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005594-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/urn:x-wiley:14651858:media:CD005594:CD005594-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_t/tCD005594-CMP-003-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Mortality, Outcome 3 Mortality (atypical versus typical antipsychotic)." data-id="CD005594-fig-0021" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Mortality, Outcome 3 Mortality (atypical versus typical antipsychotic).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/references#CD005594-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005594-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/urn:x-wiley:14651858:media:CD005594:CD005594-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_t/tCD005594-CMP-004-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse Event, Outcome 1 Antipsychotic versus no antipsychotic (EPS)." data-id="CD005594-fig-0022" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Adverse Event, Outcome 1 Antipsychotic versus no antipsychotic (EPS).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/references#CD005594-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005594-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/urn:x-wiley:14651858:media:CD005594:CD005594-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_t/tCD005594-CMP-004-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse Event, Outcome 2 Typical versus atypical antipsychotic (EPS)." data-id="CD005594-fig-0023" src="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Adverse Event, Outcome 2 Typical versus atypical antipsychotic (EPS).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/references#CD005594-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/media/CDSR/CD005594/image_n/nCD005594-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD005594-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antipsychotics versus nonantipsychotics or placebo for the treatment of delirium in hospitalised patients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antipsychotics for the treatment of delirium in hospitalised patients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> delirious patients<br/> <b>Settings:</b> hospital wards, not ICU<br/> <b>Intervention:</b> antipsychotics drugs<br/> <b>Comparison: n</b>onantipsychotics drugs or placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Non‐antipsychotics drugs or Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Antipsychotics drugs</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration of delirium</b> </p> <p>Follow‐up: days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported in any trial.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Delirium severity</b><br/> DRS, DRS‐R98, MDAS<sup>1</sup><br/> Follow‐up: up to 10 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean DRS‐R‐98 score was was 22.7 (3.1) at baseline and 7.4 (SD 3.3) at the end of study.<sup>16</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised delirium severity score was <b>1.08 points lower</b> in the intervention group (2.55 lower to 0.39 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>494<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low‐quality</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.<sup>2,3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐1.08 (‐2.55 to 0.39)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Delirium resolution</b><br/> DRS, DRS‐R98<sup>1</sup><br/> Follow‐up: up to 10 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.95</b> <br/> (0.3 to 2.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>247<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low‐quality</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.<sup>6,7,8,9,10</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>268 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>254 per 1000</b><br/> (80 to 798) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>191 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>181 per 1000</b><br/> (57 to 569) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality</b><br/> Follow‐up: up to 10 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.29</b> <br/> (0.73 to 2.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>319<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low‐quality</b>: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<sup>11,12</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>163 per 1000</b><br/> (92 to 286) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>143 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>184 per 1000</b><br/> (104 to 325) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hospital length of stay</b> </p> <p>Follow‐up: days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported in any trial.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse Effects ‐ EPS</b> <br/> Extrapyramidal Symptom Rating Scale, or not reported<br/> Follow‐up: up to 10 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.7</b> <br/> (0.04 to 65.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>247<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low‐quality</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.<sup>13,14,15</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>91 per 1000</b><br/> (2 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>DRS</b> : Delirium Rating Scale; <b>DRS‐R98</b> = Delirium Rating Scale Revised 98; <b>EPS</b> : Extrapyramidal Symptoms; <b>MDAS</b> : Memorial Delirium Assessment Scale; <b>RR:</b> Risk ratio; <b>SD:</b> standard deviation </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> DRS = Delirium Rating Scale; DRS‐R98 = Delirium Rating Scale ‐Revised 98; MDAS = Memorial Delirium Assessment Scale<br/> <sup>2</sup> Only 1 of the 4 trials was considered low risk of bias across all domains. Three of the four trials had blinded delirium assessment.<br/> <sup>3</sup> Very high heterogeneity (97%).<br/> <sup>4</sup> Delirium severity was measured with different tools at variable time points.<br/> <sup>5</sup> Wide confidence interval that included both no effect and benefit.<br/> <sup>6</sup> All included trials had risk of bias.<br/> <sup>7</sup> Blinded delirium assessment for two of the three trials.<br/> <sup>8</sup> High degree of heterogeneity (83%)<br/> <sup>9</sup> Delirium resolution was measured with different tools at variable time points using different thresholds.<br/> <sup>10</sup> Wide confidence interval.<br/> <sup>11</sup> Only 1 trial had low risk of bias across all domains.<br/> <sup>12</sup> Low number of events.<br/> <sup>13</sup> All trials at risk of bias.<br/> <sup>14</sup> Variable tools used to assess.<br/> <sup>15</sup> Few events and wide confidence intervals. </p> <p><sup>16</sup> Assumed risk taken from <a href="./references#CD005594-bbs2-0009" title="TahirTA , EelesE , KarapareddyV , MuthuveluP , ChappleS , PhillipsB , et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research2010;69(5):485‐90. ">Tahir 2010</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antipsychotics versus nonantipsychotics or placebo for the treatment of delirium in hospitalised patients</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/full#CD005594-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005594-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Typical versus atypical antipsychotics for treatment of delirium in hospitalised patients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Typical</b> versus<b>Atypical antipsychotics for treatment of delirium in hospitalised patients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> delirious patients<br/> <b>Settings:</b> hospital wards, not ICU<br/> <b>Intervention:</b> typical antipsychotic drug<br/> <b>Comparison:</b> atypical antipsychotic drug </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Atypical antipsychotic drug</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Typical antipsychotic drug</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration of delirium</b> </p> <p>Follow‐up: days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported in any trial.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Delirium resolution</b><br/> DRS, DRS‐R98<sup>1</sup><br/> Follow‐up: 7 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.1</b> <br/> (0.79 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>349<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low‐quality</b>: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>305 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>335 per 1000</b><br/> (241 to 463) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>313 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>344 per 1000</b><br/> (247 to 476) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Delirium severity</b><br/> DRS, DRS‐R98<sup>1</sup><br/> Follow‐up: 7 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean DRS‐R‐98 score was 29.7 (SD 4.6)</p> <p>8.0 (SD 6.9) at the end of study.<sup>10</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised delirium severity score was <b>0.17 points lower</b> in the intervention group (0.37 lower to 0.02 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>542<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low‐quality</b>: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.17 (‐0.37 to 0.02)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality</b><br/> Follow‐up: 7 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.71</b> <br/> (0.82 to 3.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>342<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low‐quality</b>: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>106 per 1000</b><br/> (51 to 219) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b><br/> (15 to 64) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hospital length of stay</b> </p> <p>Follow‐up: days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported in any trial.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse Effects ‐ EPS</b><br/> Follow‐up: 7 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 12.16</b> <br/> (0.55 to 269.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>198<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low‐quality</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.<sup>7,8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>DRS</b> : Delirium Rating Scale; <b>DRS‐R98</b> = Delirium Rating Scale Revised 98; <b>EPS</b> : Extrapyramidal Symptoms; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> DRS = Delirium Rating Scale; DRS‐R98 = Delirium Rating Scale Revised 98<br/> <sup>2</sup> All included trials had risk of bias.<br/> <sup>3</sup> Delirium resolution was measured with different tools at variable time points using different thresholds.<br/> <sup>4</sup> Only 1 of 7 trials was considered low risk of bias across all domains. Six of the seven trials had blinded delirium assessment.<br/> <sup>5</sup> Delirium severity was measured with different tools at variable time points.<br/> <sup>6</sup> Low number of events.<br/> <sup>7</sup> All trials at risk of bias.<br/> <sup>8</sup> Variable tools used to assess.<br/> <sup>9</sup> Few events and wide confidence intervals. </p> <p><sup>10</sup> Assumed risk taken from <a href="./references#CD005594-bbs2-0008" title="ManeetonB , ManeetonN , SrisurapanontM , ChittawatanaratK . Quetiapine versus haloperidol in the treatment of delirium: a double‐blind, randomized, controlled trial. Drug Design, Development and Therapy2013;7:657‐67. ">Maneeton 2013</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Typical versus atypical antipsychotics for treatment of delirium in hospitalised patients</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/full#CD005594-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005594-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Severity of delirium</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Antipsychotic versus no antipsychotic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.08 [‐2.55, 0.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Sensitivity analysis (placebo‐controlled studies only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.89 [‐2.64, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Sensitivity analysis (trials at low risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.22, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Typical versus atypical antipsychotic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.37, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Severity of delirium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/references#CD005594-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005594-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Resolution</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Antipsychotic versus no antipsychotic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.30, 2.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Sensitivity analysis (including placebo studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.58, 3.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Resolution (atypical versus typical antipsychotic) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.79, 1.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Resolution</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/references#CD005594-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005594-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Mortality</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality (antipsychotic versus no antipsychotic) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.73, 2.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Sensitivity analysis (including only placebo studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.75, 2.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality (atypical versus typical antipsychotic) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.82, 3.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Mortality</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/references#CD005594-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005594-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Adverse Event</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Antipsychotic versus no antipsychotic (EPS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.04, 65.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Typical versus atypical antipsychotic (EPS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.16 [0.55, 269.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Adverse Event</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005594.pub3/references#CD005594-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD005594.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD005594-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD005594-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD005594-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD005594-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD005594-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD005594-note-0002">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005594\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005594\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005594\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005594\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005594\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005594\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005594\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005594\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005594\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005594\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005594\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005594\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005594\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005594\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005594\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005594\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005594\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005594\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mvgXlmVk&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005594.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005594.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD005594.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD005594.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005594.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719691766"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005594.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719691770"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005594.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918deef258a89371',t:'MTc0MDcxOTY5Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 